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SUMMARY 
 
Acute intermittent porphyria (AIP, MIM #176000) is an inherited metabolic disease due to a 
partial deficiency of the third enzyme, hydroxymethylbilane synthase (HMBS, EC: 4.3.1.8), in 
the haem biosynthesis. Neurological symptoms during an acute attack, which is the major 
manifestation of AIP, are variable and relatively rare, but may endanger a patient’s life. 
In the present study, 12 Russian and two Finnish AIP patients with severe neurological 
manifestations during an acute attack were studied prospectively from 1995 to 2006.  
Autonomic neuropathy manifested as abdominal pain (88%), tachycardia (94%), 
hypertension (75%) and constipation (88%). The most common neurological sign was acute 
motor peripheral neuropathy (PNP, 81%) often associated with neuropathic sensory loss (54%) 
and CNS involvement (85%). Despite heterogeneity of the neurological manifestations in our 
patients with acute porphyria, the major pattern of PNP associated with abdominal pain, 
dysautonomia, CNS involvement and mild hepatopathy could be demonstrated. If more strict 
inclusion criteria for biochemical abnormalities (>10-fold increase in excretion of urinary PBG) 
are applied, neurological manifestations in an acute attack are probably more homogeneous 
than described previously, which suggests that some of the neurological patients described 
previously may not have acute porphyria but rather secondary porphyrinuria. Screening for 
acute porphyria using urinary PBG is useful in a selected group of neurological patients with 
acute PNP or encephalopathy and seizures associated with pain and dysautonomia.  
Clinical manifestations and the outcome of acute attacks were used as a basis for 
developing a 30-score scale of the severity of an acute attack. This scale can easily be used in 
clinical practice and to standardise the outcome of an attack. Degree of muscle weakness scored 
by MRC, prolonged mechanical ventilation, bulbar paralysis, impairment of consciousness and 
hyponatraemia were important signs of a poor prognosis. Arrhythmia was less important and 
autonomic dysfunction, severity of pain and mental symptoms did not affect the outcome.  The 
delay in the diagnosis and repeated administrations of precipitating factors were the main cause 
of proceeding of an acute attack into pareses and severe CNS involvement  and a fatal outcome 
in two patients. 
Nerve conduction studies and needle EMG were performed in eleven AIP patients 
during an acute attack and/or in remission. Nine patients had severe PNP and two patients had 
an acute encephalopathy but no clinically evident PNP. In addition to axonopathy, features 
suggestive of demyelination could be demonstrated in patients with severe PNP during an acute 
attack. PNP with a moderate muscle weakness was mainly pure axonal. Sensory involvement 
was common in acute PNP and could be subclinical. Decreased conduction velocities with 
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normal amplitudes of evoked potentials during acute attacks with no clinically evident PNP 
indicated subclinical polyneuropathy. Reversible symmetrical lesions comparable with 
posterior reversible encephalopathy syndrome (PRES) were revealed in two patients’ brain CT 
or MRI during an acute attack. In other five patients brain MRI during or soon after the 
symptoms was normal. The frequency of reversible brain oedema in AIP is probably under-
estimated since it may be short-lasting and often indistinguishable on CT or MRI.    
In the present study, nine different mutations were identified in the HMBS gene in 11 
unrelated Russian AIP patients from North Western Russia and their 32 relatives. AIP was 
diagnosed in nine symptom-free relatives. The majority of the mutations were family-specific 
and confirmed allelic heterogeneity also among Russian AIP patients. Three mutations, 
c.825+5G>C, c.825+3_825+6del and c.770T>C, were novel. Six mutations, c.77G>A 
(p.R26H), c.517C>T (p.R173W), c.583C>T (p.R195C), c.673C>T (p.R225X), c.739T>C 
(p.C247R) and c.748G>C (p.E250A), have previously been identified in AIP patients from 
Western and other Eastern European populations. The effects of novel mutations were studied 
by amplification and sequencing of the reverse-transcribed total RNA obtained from the 
patients’ lymphoblastoid or fibroblast cell lines. The mutations c.825+5G>C and c.770T>C 
resulted in varyable amounts of abnormal transcripts, r.822_825del (p.C275fsX2) and 
[r.770u>c, r.652_771del, r.613_771del (p.L257P, p.G218_L257del, p.I205_L257del)]. All 
mutations demonstrated low residual activities (0.1-1.3 %) when expressed in COS-1 cells 
confirming the causality of the mutations and the enzymatic defect of the disease. 
The clinical outcome, prognosis and correlation between the HMBS genotype and 
phenotype were studied in 143 Finnish and Russian AIP patients with ten mutations (c.33G>T, 
c.97delA, InsAlu333, p.R149X, p.R167W, p.R173W, p.R173Q, p.R225G, p.R225X, 
c.1073delA) and more than six patients in each group. The patients were selected from the pool 
of 287 Finnish AIP patients presented in a Finnish Porphyria Register (1966-2003) and  23 
Russian AIP patients (diagnosed 1995-2003). Patients with the p.R167W and p.R225G 
mutations showed lower penetrance (19% and 11%) and the recurrence rate (33% and 0%) in 
comparison to the patients with other mutations (range 36 to 67% and 0 to 66%, respectively), 
as well as milder biochemical abnormalities [urinary porphobilinogen  47±10 vs. 163±21 
μmol/L, p<0.001; uroporphyrin 130±40 vs. 942±183 nmol/L, p<0.001] suggesting a milder 
form of AIP in these patients. Erythrocyte HMBS activity did not correlate with the 
porphobilinogen excretion in remission or the clinical of the disease. In all AIP severity 
patients, normal PBG excretion predicted freedom from acute attacks. Urinary PBG excretion 
together with gender, age at the time of diagnosis and mutation type could predict the 
likelihood of acute attacks in AIP patients.  
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ABBREVIATIONS 
 
AIP acute intermittent porphyria 
ALA δ-aminolaevulinic acid 
ALAD δ-aminolaevulinic acid dehydratase 
ALAS δ-aminolaevulinic acid synthase 
ALT alanine aminotransferase 
bp base pair 
cDNA complementary deoxyribonucleic acid 
COS-1 simian virus 40-transformed monkey kidney cell line 
CMAP compound muscle action potential 
CNS central nervous system 
CSF cerebrospinal fluid 
CT computed tomography 
CV conduction velocity 
CYP cytochrome P-450 
DL distal latency 
DNA deoxyribonucleic acid 
DW  diffusion-weighted (magnetic resonance imaging) 
EEG electroencephalography 
EMG electromyography 
Erc-HMBS HMBS activity in erythrocytes 
FL minimal F-wave latency  
FLAIR fluid-attenuated inversion recover (magnetic resonance imaging) 
GABA gamma aminobutyric acid 
HMBS hydroxymethylbilane synthase 
HCP hereditary coproporphyria 
kb kilobase 
kD kilodalton 
MCV motor conduction velocity 
MRC Medical Research Council scale 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
PBG porphobilinogen 
PCR polymerase chain reaction 
RNA ribonucleic acid 
SCV sensory conduction velocity 
SD standard deviation 
SIADH syndrome of inadequate secretion of antidiuretic hormone 
VAS visual analogue scale 
VP variegate porphyria 
  
Mutation nomenclature meets the criteria of the Human Genome Variation Society 
(http://www.hgvs.org/mutnomen/).  
The mutation numbering was based on the cDNA sequence (c., cDNA).  
The first base of the ATG initiation Met codon was reported as nucleotide +1 
(GenBank, Ref Seq NM_000190). 
Amino acids and nucleotides are abbreviated by one-letter codes. 
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1. INTRODUCTION 
 
Acute intermittent porphyria (AIP, MIM #176000) is an inherited metabolic disease due to a 
partial deficiency of the third enzyme, hydroxymethylbilane synthase (HMBS, also named 
porphobilinogen deaminase, PBGD, EC: 4.3.1.8), in the haem biosynthesis (Anderson et al. 
2001). The major clinical manifestation of AIP is an acute attack, which includes mental 
symptoms, abdominal pain and signs of autonomic dysfunction accompanied by increased 
excretion of porphyrin precursors originating from the liver and releasing into the circulation 
(Kauppinen 2005).  Most of the attacks are short and self-limited. In a protracted attack, acute 
peripheral neuropathy (PNP) and signs of CNS involvement may occur (Goldberg 1959; Ridley 
1969; Stein, Tschudy 1970). Since an acute attack may endanger life, a rapid diagnosis is 
essential because an effective treatment is available (Mustajoki, Nordmann 1993).  The overall 
prevalence of AIP is 1-10:100 000 (Anderson et al. 2001).  However, the misdiagnosis is not 
rare (McEneaney et al. 1993), and thus, the prevalence may be underestimated. Most of the 
studies on neurology in porphyria were published 30 to 50 years ago (Waldenström 1937; 
Schwarz, Moulton 1954; Goldberg 1959; Ridley 1969; Stein, Tschudy 1970; Sorensen, With 
1971) before the DNA-diagnostics of AIP became available. Neuroimaging has enabled more 
precise understanding of encephalopathy in acute porphyria. Because of improved diagnostics 
and early and more effective treatment of acute attacks, severe neurological manifestations 
have become rare. The pathogenetic mechanisms of neurological manifestations in AIP are still 
obscure and unknown at the molecular level (Meyer et al. 1998).  
Mutation screening is useful for confirmation of the diagnosis of AIP in symptomatic 
patients and for family studies. In remission, mutation screening of the HMBS gene is currently 
the most reliable method to diagnose AIP and it has been applied to the routine diagnostics of 
AIP in many countries.  In contrast, no such systemic studies to identify underlining mutations 
in AIP patients have previously been performed in Russia. At the beginning of this study in 
1995 a few cases of acute porphyria have been diagnosed clinically in North Western Russia 
including St Petersburg.  
The aim of this study was to characterise neurological manifestations of AIP, 
precipitating factors and the natural course of an acute attack, efficiency of the treatment, and 
the short-term and long-term outcomes of patients with AIP. Based on that information, the 
scale of the severity of an acute attack could be established. The pathogenesis of acute PNP and 
encephalopathy during an attack could be elucidated by neurophysiological studies and 
neuroimaging. The characterisation of the HMBS gene defects allowed the precise diagnosis in 
these patients. Finally, a genotype-phenotype correlation could be established.  
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2. REVIEW OF THE LITERATURE 
 
2.1. PORPHYRIAS 
 
2.1.1. Porphyrias and haem biosynthesis  
 
Porphyrias constitute a group of inherited metabolic disorders caused by defective functions of 
the enzymes in the haem biosynthesis. Each of seven porphyrias results from a partial 
deficiency of one of the enzymes in the haem biosynthetic pathway (Figure 1).  
 
 
 
Enzyme 
  
Metabolic pathway 
 
Glycine + Succinyl-CoA 
 
Type of porphyria  
 
    
 
    
 ALA–dehydratase 
deficiency porphyria 
 
     
Hydroxymethylbilane 
synthase (HMBS) 
  Acute intermittent 
porphyria (AIP) 
 
  [Hydroxymethylbilane]   
Uroporphyrinogen III 
synthase 
  Congenital  
erythropoetic porphyria 
 
  Uroporphyrinogen III   
Uroporphyrinogen 
decarboxylase 
  Porphyria  
cutanea tarda 
 
  Coproporphyrinogen III   
Coproporphyrinogen 
oxidase 
  Hereditary 
coproporphyria 
 
  Protoporphyrinogen IX   
Protoporphyrinogen 
oxidase 
 
 
Variegate 
 porphyria 
 
  Protoporphyrin  IX   
Ferrochelatase    Erythropoetic 
protoporphyria 
 
 
 
            Haem 
 
  
 
Figure 1. Haem biosynthesis and different porphyrias 
 
Haem is synthesised in every human aerobic cell (Ponka 1999; Ajioka et al. 2006). Most of 
the haem is synthesised in erythroid cells and in the liver. Heam is used as a prosthetic group of 
haemoproteins, which are responsible for oxidative reactions, electron transfer processes and 
delivering molecular oxygen to cells (Ajioka et al. 2006).  In erythroid cells haem enhances 
transcription and translation of globin and other erythroid-specific proteins. In nonerythroid 
cells haem regulates expression or stability of hemoproteins. 
 
Porphobilinogen (PBG)
δ-aminolaevulinic 
acid dehydratase  
(ALA–dehydratase) 
δ-aminolaevulinic acid (ALA) 
δ-aminolaevulinic acid 
synthase (ALAS) 
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Figure 2. Haem byosynthesis in the cell 
Ac, -CH2COOH; Pr, -CH2CH2COOH; Vi, -CH=CH2 
 
Heme oxygenase, which catalyses heme degradation, provides biliverdin and thus, plays a role 
in an antioxidant system (Ponka 1999). 
Coproporphyrinogen III Protoporphyrinogen IX 
Protoporphyrin IX 
Haem 
Succinil CoA 
Glycine 
δ-aminolaevulinic acid (ALA) 
Porphobilinogen 
Hydroxymethylbilane 
Uroporphyrinogen III 
Protoporphyrinogen oxydase 
Ferrochelatase 
Coproporphyrinogen oxidase 
Hydroxymethylbilane 
synthase  
ALA 
dehydratase ALA synthase  
Uroporphyrinogen III 
synthase 
Uroporphyrinogen III 
dexarboxylase 
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Haem biosynthesis is illustrated in Figures 1 and 2. The first and the last three steps take 
place in mitochondria and the intermediate steps are cytosolic. δ-Aminolaevulinic acid (ALA) 
and porphobilinogen (PBG) are precursors of tetrapyrroles, named porphyrins. The haem 
biosynthetic pathway may be presented as four basic processes: formation of the pyrrole, 
assembly of the tetrapyrrole, modification of the tetrapyrrole side chains and oxidation of 
protoporphyrinogen IX to protoporphyrin IX and insertion of iron (Ajioka et al. 2006). Iron 
molecule coordinated within the tetrapyrrole allows haem to have diverse functions as an 
electron carrier and a catalyst for redox reactions (Ajioka et al. 2006). 
For the first four enzymes in the pathway both housekeeping and erythroid transcripts 
are produced (Table 1). The housekeeping aminolaevulinate synthase 1 (ALAS1) and erythroid-
specific ALAS2 are encoded by different genes (Bishop et al. 1990). The different transcripts 
for aminolaevulinate dehydratase (ALAD), hydroxymethylbilane synthase (HMBS) and  
uroporphyrinogen III synthase are synthesised via alternative splicing of the transcript, and the 
corresponding genes contain tissue-specific promoters (Anderson et al. 2001). 
ALAS is the rate-limiting enzyme of haem biosynthesis (Anderson et al. 2001). In the 
liver, haem represses synthesis of ALAS1 at transcriptional and translational levels  (May et al. 
1995; Fraser et al. 2002). ALAS1 is induced directly by numerous drugs, chemicals and alcohol 
(Fraser et al. 2002) or by peroxisome-proliferator-activated receptor γ coactivator 1α (PGC-1α). 
The transcription of PGC-1α  is induced under low glucose concentration (Handschin et al. 
2005). In addition, some drugs induce the haem-containing cytochrome P450 enzymes (CYP 
450) (Anderson et al. 2001); and the stress activates hepatic haem oxygenase (Rodgers, 
Stevenson 1990). These factors result in decreased hepatic haem concentrations and 
consequently a loss of negative feedback to ALAS1. Induction of ALAS1 leads to 
overproduction of haem precursors in the liver, and accumulation of them in other tissues via 
circulation (Anderson et al. 2001). In erythroid cells, haem induces synthesis of ALAS2 mRNA 
(Smith, Cox 1997). In acute porphyrias, porphyrin precursors do not accumulate in the bone 
marrow (Anderson et al. 2001). 
Dipyrromethane serves as a cofactor for the reaction catalysed by HMBS (Shoolingin-
Jordan 1995). Dipyrromethane is a product of autocatalytic coupling of PBG, the same 
molecule, which is a substrate for the reaction. Recent studies on dipyrromethane cofactor 
assembly mechanism have shown that elevated PBG strongly inhibits the formation of holo-
HMBS-deaminase from apo-HMBS-deaminase (Shoolingin-Jordan et al. 2005).  It was 
suggested, that PBG levels measured during acute attacks of porphyria were high enough to 
inhibit the formation of holo-HMBS and to reduce dramatically the activity of hepatic HMBS in 
vivo, which could contribute to overproduction of porphyrin precursors during an acute attack 
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(Shoolingin-Jordan et al. 2005). A 3.4-fold decrease in the activity of hepatic HMBS was 
observed when an AIP patient during an acute attack was compared with two other AIP patients 
in remission (Strand et al. 1970). This finding could indirectly support the hypothesis 
mentioned above (Shoolingin-Jordan et al. 2005). 
Some chemicals and toxins are known to reduce the activity of other enzymes of the 
haem-biosynthesis. Lead can reduce dramatically the activity of ALAD (Godwin 2001), while 
arsenic and alcohol reduce the activities of uroporphyrinogen decarboxylase and 
coproporphyrinogen oxidase (Woods, Southern 1989; Doss et al. 2000).  
 
2.1.2. Molecular genetics of porphyrias 
 
The genes involved in the haem biosynthesis have been characterised (Table 1). A lot of 
mutations in these genes are responsible for different types of porphyria, demonstrating allelic 
heterogeneity of each of them (http://www.hgmd.cf.ac.uk). Mutations in ALAS2 gene are 
responsible for X-linked inherited sideroblastic anaemia (Shoolingin-Jordan et al. 2003). 
Porphyrias are mainly inherited autosomal dominant disorders with incomplete penetrance 
(Anderson et al. 2001) (Table 1). 
 
Table 1. Molecular genetics of porphyria 
 
Enzyme  Gene 
Nomenclature Transcripts  Symbol Size Location 
Muta-
tions 
Inhe-
ritance 
Aminolaevulinate  
synthase 
ALAS1 housekeeping  
ALAS2 erythroid-specific 
 ALAS1  
ALAS2 
17 kb 
22 kb 
3p21.1 
Xp11.21 
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X-linked 
Aminolaevulinate 
dehydratase 
ALAD housekeeping  
ALAD erythroid-specific  
 ALAD  7 kb 9q34   9 AR 
Hydroxymethylbilane 
synthase 
HMBS housekeeping 
HMBS erythroid-specific  
 HMBS  10 kb 11q23.3 244 AD 
Uroporphyrinogen III 
synthase 
UROS housekeeping  
UROS erythroid-specific 
 UROS  34 kb 10q25.2-
q26.3 
 36 AR 
Uroporphyrinogen 
decarboxylase 
  UROD  3 kb 1p34  65 AD/Ac 
Coproporphyrinogen  
oxidase 
  CPO  14 kb 3q12  37 AD 
Protoporphyrinogen 
oxidase 
  PPOX  5.5 kb 1q22 129 AD 
Ferrochelatase   FECH  45 kb 18q21.3  88 AD/AR 
 
AR, autosomal recessive; AD, autosomal dominant; Ac, acquired 
  
2.1.2.1. Hydroxymethylbilane synthase (HMBS) gene  
 
The HMBS gene includes 15 exons (Figure 3, GenBank, Ref Seq NC_000011). Two different 
mRNAs, one for erythroid and the other for non-erythroid tissues, are transcribed via two 
promoters and processed by alternative splicing. Erythroid mRNA includes exons 2-15, and 
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non-erythroid mRNA exons 1 and 3-15 (Grandchamp et al. 1987; Gubin, Miller 2001). Small 
amounts of other alternatively spliced transcripts both for erythroid (Gubin, Miller 2001) and 
housekeeping mRNAs (Ong et al. 1998) have been found in healthy subjects. 
Mutations in the HMBS gene result in a loss of function or instability of a  
mutant transcript.  Heterozygous patients have approximately 50% of the total  HMBS activity 
measured in their erythrocytes, lymphocytes, fibroblasts and hepatocytes (Strand et al. 1970; 
Meyer et al. 1972; Sassa et al. 1975; Sassa et al. 1978). This is sufficient to maintain the normal 
demand for haem (Anderson et al. 2001)  
 
 
Figure 3. The HMBS gene and two mRNAs transcribed by alternative splicing. 
 
2.1.2.2. Haem metabolism in neural tissues 
 
Many haemoproteins are detected in the brain. While neuroglobin and nitric oxide synthase 
(NOS) type I are specific for neural tissues, cytochromes and soluble guanilate cyclase are 
found in every cell (Anderson et al. 2001). Astrocyte CYP 450 is essential for degradation of 
xenobiotics, and thus, mediates their toxicity  (Meyer et al. 2001). Since exogenous radiolabeled 
haematin was not detected in the rat brain homogenates after intravenous injection (De Matteis 
et al. 1981), it was concluded that haem is not able to cross the blood-brain barrier. Thus, there 
is de novo production of the required haem in the brain. (De Matteis et al. 1981). In the rat brain 
tissues, distinct staining with anti-HMBS antibodies has demonstrated, that the highest 
immunoreactivity occurs in axons of the corpus striatum (Jorgensen et al. 2000). In the brain of 
the adult mice and rat, the activity of ALAS1 was only 20-24% of that in the liver  (De Matteis, 
Zetterlund et al. 1981; Gorchein 1990).  
The regulation of the haem biosynthesis in the nervous tissues is not currently clear 
(Anderson et al. 2001). Potential inducers of hepatic ALAS1 had no effect on ALAS activity in 
HMBS gene 
Erythroid 
Housekeeping 
            mRNA 
Initiation codon Termination codon 
1 15 14 13121110987654 3 
15 14 13121110987654 3 2 
100 bp
5' 3'
1000  bp
1  10        11  12  13 15
14 
 2 3   4    5 6     7   8 9 
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the rat brain  in one study (Paterniti et al. 1978) suggesting  that excess of porphyrin precursors 
in neural tissues is due to their production in the liver (Kauppinen 2005). This observation is 
supported by the fact that the liver transplantation in an AIP patient with severe recurrent 
attacks resulted in a full biochemical and clinical remission (Soonawalla et al. 2004). However, 
the recent study has demonstrated 80-240% increase in ALAS1 activity and mRNA expression 
in the brain samples of  normal mice treated with porphyrinogenic drugs (Rodriguez, Martinez 
Mdel et al. 2005). This suggests that intra-neural synthesis of porphyrin precursors may 
contribute to neurological manifestation of an acute attack. 
 
2.1.3. Acute porphyrias   
 
Porphyrias are classified as erythropoetic and hepatic depending on the major tissue of 
production and accumulation of porphyrins and their precursors (Moore et al. 1987) (Figure 4). 
All hepatic porphyrias, except porphyria cutanea tarda, have similar clinical manifestations with 
acute neurovisceral crises, so-called acute attacks. This is accompanied by reddish dark urine 
representing porphobilin and porphyrin excess (Anderson et al. 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Classification of porphyrias 
 
Acute intermittent porphyria (AIP, MIM #176000) results from a partial deficiency of 
HMBS (also known as porphobilinogen deaminase, EC: 4.3.1.8), the third enzyme in the 
pathway. AIP has an autosomal dominant pattern of inheritance. It is the most common type of 
acute porphyrias (Anderson et al. 2001). Acute attacks of AIP are clinically indistinguishable 
from other acute porphyrias, but in AIP they occur more often than in other types of porphyria, 
namely in variegate porphyria (VP) (Hift, Meissner 2005). In contrast to AIP, dermatological 
Erythropoetic 
porphyrias 
   Hepatic 
   porphyrias 
Congenital 
erythropoetic 
porphyria 
 
Erythropoetic 
protoporphyria
Porphyria cutanea tarda 
Acute 
porphyrias 
ALA-dehydratase deficiency 
porphyria 
 
Acute intermittent porphyria 
 
Hereditary coproporphyria 
 
Variegate porphyria 
P O R P H Y R I A S 
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features such as photosensitivity, skin fragility, vesicular rash and hypertrichosis are found in 
14%- 80% of patients with VP and hereditary coproporphyria (HCP) (Whatley, Puy et al. 1999; 
Kuhnel et al. 2000; von und zu Fraunberg et al. 2002). Those features are usually independent 
from acute attacks and are probably caused by free radical damage by porphyrins in the skin 
(Poh-Fitzpatrick 2000).  
 
 
2.1.4. History of acute intermittent porphyria 
 
Some historical figures with paroxysmal aberrant behavior have been suggested to suffer from 
acute porphyria. Among them were King George III, Van Gogh, and Alexander the Great 
(Moore et al. 1987; Oldach et al. 1998; Arnold 2004). In none of these cases the diagnosis of 
acute porphyria has been proven and it is only highly speculative. The varying manifestations of 
congenital erythropoetic porphyria have led to legendary descriptions of patients comparing 
them with vampires and were-wolfs (Moore et al. 1987). 
The first description of a drug induced acute porphyria was published in 1889. The 
patient was an elderly woman who had red urine and died of ingestion of sulphonal, a 
barbiturate hypnotic (Stokvis 1889).  One year later Ranking and Pardington described two 
similar cases who in addition suffered from generalised muscle weakness (Ranking, Pardington 
1890). This probably represents the first description of neurological manifestations of acute 
porphyria. In 1934, Fisher was the first to show, that porphyria is caused by the impaired haem 
biosynthesis (Fisher, Orth 1934).  Later, Watson together with Schwartz developed a qualitative 
screening-test for PBG in the urine, which could be used to confirm the diagnosis of an acute 
porphyric attack (Watson, Schwartz 1941). Waldenström, who worked in Fisher's laboratory, 
reported in 1937 a series of 100 northern Swedish patients with acute porphyria (Waldenström 
1937; Waldenström 1939). The diagnosis was confirmed later by mutation screening. The  
major mutation in the HMBS gene was found to be responsible for AIP with high prevalence in 
the northern part of Sweden (Lee, Anvert 1991).  
The only systematic neurological evaluation in a sufficiently large group of patients 
(n=25) with acute PNP during an acute attack has been performed by Ridley (Ridley 1969). In 
this study, the characteristics of PNP in acute porphyria were outlined and this study has been 
the main source of knowledge for neurological manifestations in acute porphyria for the 
following 30 years. Detailed neurophysiological studies and neuroimaging are lacking in his 
description, which are currently the key elements in neurological diagnostics, and quantitative 
assessment of urinary PBG was available only in seven cases. 
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Cloning of the HMBS gene and its complete sequencing (Raich et al. 1986; Chreitien et 
al. 1988; Lee 1991) resulted in detection of various mutations in the HMBS gene. This has 
demonstrated allelic heterogeneity of AIP in different populations (Kauppinen et al. 1995; 
Rosipal et al. 1997; Floderus et al. 2002; Gregor et al. 2002; Parera et al. 2003). 
Porphyrias in Russia have been studied by Idelson since 1960s (Idel'son et al. 1992), and 
currently, the clinical and biochemical studies are conducted in the Center of Haemotology of 
Russian Academy of Science in Moscow (Surin et al. 2001; Pustovoit et al. 2003) 
 
2.2. CLINICAL MANIFESTATIONS OF AIP 
 
2.2.1. Prevalence 
 
AIP is the most common type of acute porphyria in all countries except South Africa and Chile 
where VP is the most common one (Armas et al. 1992; Hift, Meissner 2005). AIP is found in all 
ethnic groups and the prevalence varies from 1 to 10:100 000 (Table 2). The misdiagnosis is 
frequent, and thus, these numbers may not represent the true frequency. The founder effect is 
responsible for higher prevalence of AIP in some regions (Table 2).  
 
Table 2. Prevalence of AIP in different countries 
 
Country Prevalence* Reference 
Finland  3/100 000 Mustajoki, Koskelo 1976  
Sweden (whole) 10/100 000 Floderus et al. 2002 
Sweden (province Arjeplog) 2 000/100 000 Andersson et al. 1995 
Sweden (province Arvidsjaur) 500/100 000 Andersson et al. 1995 
Norway (whole) 10/100 000 Tjensvoll, Bruland et al. 2003 
Norway (Saltdal region) 600/100 000 Tollali et al. 2002 
Western Australia 3/100 000 Saint and Curnow 1962 
USA 5-10/100 000 Tschudy et al. 1975 
Japan 1.5/100 000 Sugimura 1995 
Argentina 0.8/100 000 Parera et al. 2003 
* Including symptom-free patients 
 
When 2234 Finnish and 3350 French healthy donors (Mustajoki et al. 1992a; Nordmann 
et al. 1997) were assessed for the low erythrocyte HMBS activity, 1:500 to 1:1500 prevalence 
values was observed suggesting that the prevalence of the low HMBS might be much higher 
than previously estimated.  
There is no statistical data available for the prevalence of AIP in Russia with a 
population of ~140 million, since only single cases were reported which were mainly 
concentrated around Moscow and St Petersburg. In Russia, Belarus and Uzbekistan (Pustovoit 
et al. 2003), a total of 42 AIP patients have been reported to date. However, only in four cases, 
AIP was confirmed by mutation analysis (Surin et al. 2001). 
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2.2.2. Clinical picture of AIP 
 
2.2.2.1. Acute attacks 
 
The main clinical manifestation of AIP is an acute attack, which is a neurovisceral crisis 
manifesting as a combination of signs and symptoms listed in Table 3.  
 
Table 3. Clinical manifestation during an acute attack in different patient series  
 
Signs and symptoms  1 
n=252 
2 
n=50 
3 
n=40(34)‡
4* 
n=88 
5† 
n=51/22¶ 
6* 
n=112/24¶ 
 % % % % % % 
I. Autonomic dysfunction       
 Abdominal pain 85 94 95 95 96 97 
 Tachycardia (>80 per min) 28 64 80 85 79  38 
 Hypertension  40 54 36 55 57 74 
 Constipation 48 84 48 80 78 27 
 Vomiting and nausea 59 88 43 80 84 79 
 Bladder paresis n.a. n.a. 12 n.a. n.a. n.a. 
II. Peripheral neuropathy or/and encephalopathy 
 Pain in the back and limbs n.a. 52 50 70 25 n.a. 
 Mental symptoms 55 58 40  40 19 1§  
 “Pareses” / ”Muscle weakness”  42 68 60 50 8 46/10¶  
 Epileptic seizures 10 16 20 20 2 5 
III. Metabolic changes       
 Hyponatraemia  n.a. 25 26 61 32 31 
  Transaminases increased n.a. n.a. 13 n.a. n.a. n.a. 
 Red/ dark  urine n.a. n.a. 74 90 90 n.a. 
 
1 Waldenström, 1957; 2 Goldberg, 1959; 3 Stein, Tchudy; 4  Mustajoki, 1976; 5 Mustajoki, Nordmann, 
1993;  6 Hift, Meissner, 2005  
*AIP and VP. † Cases early treated with haem arginate. ‡40 cases with full and 34 with partial 
information available. ¶ Attacks/patients. § Only psychosis is included.    
n.a., not applicable 
 
In the majority of the series, motor deficit was described as “paresis” or “muscle weakness”. In 
those cases, retrospective categorisation of this neurological sign was not possible, since from 
the data published it was not possible to determine precisely the cause of muscle weakness. 
 
Autonomic dysfunction 
Pain in the back and limbs 
Hyponatraemia 
Mental symptoms 
Muscle weakness 
Dark urine 
 
Figure 5. Common combination of symptoms during an acute attack 
 
The signs and symptoms appear usually in combination. The severity of each symptom 
and the combination of the symptoms vary among patients. None of the symptoms and/or signs 
Abdominal 
pain + 
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are pathognomonic, but their co-occurrence together with abdominal pain should suggest acute 
porphyria (Mustajoki, Koskelo 1976) (Figure 5).    
 
2.2.3. Neurological manifestations of an acute attack 
 
The majority of acute attacks manifest only as a combination of abdominal pain, mild mental 
symptoms and autonomic dysfunction and without PNP or focal CNS impairment (Mustajoki, 
Nordmann 1993). Only if an attack proceeds, various signs of neurological deficits may develop 
(Table 4).  
 
Table 4. The common signs of neurological impairment during an acute attack in different series  
 
 
1  Goldberg, 1959; 2  Ridley, 1969: 3 Stein, Tchudy; 4 Mustajoki, 1976; 5  Mustajoki, Nordmann, 1993 
* All patients with PNP; † Attacks/patients; ‡40 cases with full and 35 with partial information available;  
§The origin of optic neuritis was suggested. n.a., not applicable 
 
Neurological manifestations of AIP are great imitators leading to potential misdiagnosis 
in these patients (Waldenström 1939; Goldberg 1959; Ridley 1969; Crimlisk 1997) (Table 5). 
The paroxysmal nature of the attacks and the almost uniform and specific temporal association 
of neurological features with acute abdominal pain is characteristic for acute porphyria 
(Goldberg 1959). When progressive muscle weakness manifests, the intensity of abdominal 
pain may decline (Goldberg 1959; Stein, Tschudy 1970; Hift, Meissner 2005), which may lead 
to misdiagnosis.  
 
  Signs and symptoms 
   
 1 
n=50 
 2* 
n=29/25† 
3 
n=40(35)‡ 
4 
n=88 
5 
n=51/22† 
 % % % % % 
 I Peripheral neuropathy      
 Muscle weakness 68 100 60 50  8 
 Low/absent tendon reflexes 54  97 29 n.a. n.a. 
 Respiratory paresis 10  55  9 20  0 
 Cranial neuropathy 28  69 54 15  0 
 Neuropathic sensory loss  38  59 26 25 n.a. 
 II. Encephalopathy      
 Seizures 16  21 20 20  1 
 Mental symptoms 58  86 40 40 19 
 Coma n.a. n.a. 10 n.a.  0 
 Blurred vision  6§  7§  6§ n.a.  2 
 Babinski signs 10  3  3 n.a. n.a. 
 Nystagmus 
Cerebellar ataxia 
 2 
 2 
 7 
 0 
 0 
 0 
n.a. 
n.a. 
n.a. 
 0 
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Table 5. The common neurological misdiagnoses in patients with acute porphyria*  
 
Diseases with predominant 
CNS involvement 
Diseases with predominant 
involvement of peripheral nerves 
Diseases with predominant 
involvement of autonomic 
nerves 
Viral/ toxic encephalopathy  
 
Seizures 
Acute inflammatory PNP 
(=Guillain-Barré syndrome)  
Acute PNP of other origin 
Panic disorder  
(“crises vasculares”)  
Rheumatic fever 
Psychosis Polymyositis  
Fatigue Poliomyelitis  
Hysteria   
 
*by Waldenström 1939; Goldberg 1959; Ridley 1969; Crimlisk 1997 
 
The incidence of neurological manifestations has decreased over the years mainly 
because of greater awareness and early treatment of the attacks. In the series of 50 AIP patients 
published in 1959, 68% of them had paresis and 16% had epileptic seizures (Goldberg 1959). 
30 years later Mustajoki  and Nordmann reported 51 attacks in 22 patients, who have been 
treated with haem arginate at the early phase of an attack. Among those, 8% of the patients 
experienced mild and moderate pareses without respiratory involvement and only one patient 
had seizures (Mustajoki, Nordmann 1993). 
 
2.2.3.1. Autonomic neuropathy  
 
Autonomic neuropathy is responsible for the majority of symptoms in an acute attack (Table 3). 
Tachycardia is usually associated with the activity of the disease (Ridley et al. 1968). 
Orthostatic hypotension (Stein, Tschudy 1970), diastolic hypertension (Goldberg 1959; Stein, 
Tschudy 1970), diarrhoea (Stein, Tschudy 1970; Mustajoki, Koskelo 1976) and erectile 
dysfunction (Goren, Chen 1991) have been occasionally observed.  
 During an acute attack abnormal parasympathetic cardiac reflexes were demonstrated in 
eight AIP patients using the battery of standard Ewing’s tests (Ewing et al. 1985; Laiwah et al. 
1985). Of two sympathetic tests, the postural drop of blood pressure was normal and the blood 
pressure response to sustained hand-grip was slightly decreased (Laiwah et al. 1985). These 
results are questionable, since six of the patients had motor PNP during the acute attack. The 
vagal insufficiency rather than sympathetic activation is more likely explanation for cardiac 
dysautonomia in AIP. The other signs of cholinergic insufficiency are constipation and bladder 
paresis (Freeman 2005). The mechanisms of these phenomena are currently quite speculative, 
since no appropriate bowel emptying or urodynamic tests have been reported in AIP patients.  A 
patient with HCP and chronic intestinal pseudo-obstruction was described (Vassallo et al. 
1992), suggesting severe vagal insufficiency, but the diagnosis of HCP was questionable 
(Pierach 1992). 
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 Cholinergic insufficiency does not explain postural hypotension, diarrhea and excessive 
sweating (Stein, Tschudy 1970). These symptoms are probably due to sympathetic insufficiency 
(Freeman 2005).  
 The origin of nausea and vomiting in acute porphyria is unknown (Meyer et al. 1998). 
Both abnormal bowel motility and central mechanisms may be involved.  
Reduced heart rate variability found in 23 patients with AIP in remission, (Blom et al. 
1996) and abnormal response to Valsalva maneuver in 10 asymptomatic patients with AIP 
(Laiwah et al. 1985) suggested chronic cardiac dysautonomia with cholinergic insufficiency 
(Blom et al. 1996). The tests of sympathetic function in those patients were normal (Laiwah et 
al. 1985; Blom et al. 1996).  
 In summary, autonomic neuropathy in acute porphyria manifests as pandysautonomia, 
(Laiwah et al. 1985; Freeman 2005) with parasympathetic insufficiency predominance.  
 
2.2.3.2. Acute peripheral neuropathy 
 
Acute PNP is the most common neurological complication of an acute attack (Goldberg 1959; 
Ridley 1969; Stein, Tschudy 1970). It manifests as diffuse muscle weakness, symmetrically 
distributed hyporeflexia and sensory loss (McLeod 1995), which appear during an acute attack. 
Similar to classical polyneuropathies, the distribution of muscle weakness is symmetrical and 
evenly distributed in the proximal and distal muscle groups of the upper extremities. In the 
lower extremities the weakness is pronounced in the proximal muscles (Ridley 1969). 
 Another outstanding feature of PNP in acute porphyria is the preservation of the ankle 
jerks in about half of patients while otherwise there is global areflexia (Ridley 1969). 
Respiratory failure, the most severe complication of muscle weakness because of diaphragm 
paresis, was common in the earlier series (10%-64%) (Goldberg 1959; Ridley 1969; Stein, 
Tschudy 1970; Mustajoki, Koskelo 1976) but was not seen in AIP patients treated in the early 
phase of an acute attack (Mustajoki, Nordmann 1993).  
 The sensory symptoms of PNP are usually due to irritation (painful paresthesia, 
hyperesthesia) (Tschudy et al. 1975) which may be misdiagnosed as conversion. Sensory loss is 
less common. Both “glove-and-stocking” or patchy proximal distribution of sensory loss 
atypical for length-dependant polyneuropathies have been described (Ridley 1969). Cranial 
neuropathy affecting mainly III, VI, IX and X cranial nerves is present in 35-55% of acute 
attacks with PNP (Ridley 1969; Stein, Tschudy 1970). 
 Motor polyneuropathy without abdominal pain was reported only in a few cases with 
AIP (Ridley 1969; Goren, Chen 1991; Niznikievicz, Jablonska-Kaszewska 1996; Cohen et al. 
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1997; Andersson et al. 2002). A predominantly motor type of PNP accompanied by abdominal 
pain has been described in the majority cases with AIP. Single cases of mononeuritis multiplex 
(Ridley 1969; King et al. 2002), focal motor polyneuropathy (Ridley 1969), predominantly 
sensory polyneuropathy (Goren, Chen 1991), retrobulbar neuritis (Wolter et al. 1972), "pseudo 
myopathy" ( Cohen et al. 1997; Poersch 1998), "pseudo myasthenia" (Goldberg 1959) and 
severe ptosis without ophathalmoplegia (Tan et al. 1990) during an acute attack of AIP have 
been published. This suggests that patients with AIP may have variable neurological 
manifestations during an acute attack. In some of the cases, however, the diagnosis of acute 
porphyria was based on inadequate biochemical diagnostics or their interpretation, and thus, 
acute porphyria might not be the cause of those symptoms (Tan et al. 1990; Goren, Chen 1991; 
Cohen et al. 1997). 
  The routine examination of cerebro-spinal fluid (CSF) in patients with AIP and PNP is 
usually normal (Goldberg 1959; Ridley 1969; Nagler 1971; McEneaney et al. 1993), indicating 
the absence of neuroinflammatory process in the CNS and the proximal nerves. 
 
2.2.3.3. Acute encephalopathy 
 
 Single cases of transient cortical blindness (Lai et al. 1977; Kupferschmidt et al. 1995; Garg et 
al. 1999; Yen et al. 2002; Wessels et al. 2005), hemianospia (Martin, Heck 1956), cerebellar 
ataxia (Gibson, Goldberg 1956; Crimlisk 1997), parkinsonism (Ridley 1969; Crimlisk 1997), 
finger tremor (Ridley 1969), dysphasia (Aggarwal et al. 1994) and central pontine myelinolysis 
(Susa et al. 1999) have been published, but in general, focal CNS involvement is rare during an 
acute attack. Of 25 patients with PNP during an attack, only one manifested extensor plantar 
response without other clinical signs of CNS involvement (Ridley 1969). In this case, the focus 
of haemorrhagic infarction in the contralateral internal capsule was revealed on autopsy.   
Of 224 patients,  4-61 % had hyponatraemia during an acute attack (Goldberg 1959; 
Ridley 1969; Stein, Tschudy 1970; Mustajoki, Koskelo 1976; Hift, Meissner 2005),  which in 
the absence of diarrhea, vomiting and polyuria, is usually a manifestation of the syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH) (Suarez et al. 1997). Generalised or 
focal epileptic seizures, which accompany 2% to 20% of acute attacks (Stein, Tschudy 1970; 
Mustajoki, Nordmann 1993; Bylesjo et al. 1996), have mainly been attributed to hyponatraemia.  
Aberrant behavior and various psychiatric manifestations, so-called mental syndrome of 
acute porphyria (Wettenberg 1967), appear transiently during an acute attack (Table 3). 
Frequencies of these manifestations vary from series to series (19% - 56%). This may be due to 
underestimation of mild mental symptoms or different severity of the attacks in these series.  
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In remission no segregation of acute porphyria and schizophrenia or bipolar disorder was found 
in a large series of 344 AIP patients in Glasgow (Patience et al. 1994), however anxiety was 
more common among AIP patients than in general population (Patience et al. 1994; Millward et 
al. 2005).  
CSF in patients with encephalopathy during an acute attacks was normal (Aggarwal et 
al. 1994; Kupferschmidt et al. 1995; Utz et al. 2001; Celik et al. 2002; Engelhardt et al. 2004; 
Maramattom et al. 2005; Wessels et al. 2005). 
 
2.3. PRECIPITATING FACTORS 
 
Both endogenous and exogenous precipitating factors, such as certain medications, alcohol, 
infections, low caloric intake or changes in sex hormone balance during the menstrual cycle or 
pregnancy, can provoke clinical manifestations in AIP (Goldberg 1959; Stein, Tschudy 1970; 
Kauppinen, Mustajoki 1992). Information about potentially safe and unsafe drugs can be found 
on the Internet (e.g. www.porphyria-europe.com, www.uq.edu.au/porphyria, 
www.uct.ac.za/depts/porphyria).  
           The major endogenous factor is the hormonal cycle. In women with diagnosed AIP the 
menstrual cycle is the most common (30%) precipitating factor of an acute attack manifesting 
usually with one to three months interval in premenstrum (Herrick et al. 1990; Kauppinen, 
Mustajoki 1992; Anderson et al. 2001). Previously, pregnancies were commonly complicated 
by acute attacks mainly during the first trimester and postpartum (Shapiro et al. 1969; Hunter 
1971; Wenger et al. 1998).  Currently, overall prognosis for pregnancy in AIP is good, 
especially, if the diagnosis is known in advance and no porphyrinogenic drugs are used 
(Kauppinen, Mustajoki 1992; Andersson et al. 2003).  
The exact mechanism of endogenous hormonal fluctuations causing acute attacks is 
unknown. The direct role of sex hormones as precipitating factors is unlikely, since attacks 
during the second and third trimester of pregnancy are rare, when the level of sex hormones is 
at the highest (Pischik, Kauppinen 2006). Moreover, cyclical attacks occur usually in 
premenstrum, when the level of oestrogen and progesterone is fluctuating the most. The central 
role of the hypothalamic suprachiasmatic clock area in maintaining recurrent attacks of AIP has 
been suggested (Pischik, Kauppinen 2006). Gamma amino butyric acid (GABA) mediated 
neurons from the clock area have been shown to control directly liver metabolism via 
autonomic nerves (Kalsbeek et al. 2004), which could link circadian rhythms and cyclic attacks 
of AIP. The high affinity of ALA to GABA receptors has been demonstrated in vitro (Brennan, 
Cantrill 1981), and thus, overproduction of ALA can affect synchronisation and the threshold of 
 24
the GABA-ergic clock cells. This may activate abnormal liver metabolism and, consequently, 
precipitate acute attacks by the central mechanism, making AIP a CNS disorder in addition to a 
liver disease (Pischik, Kauppinen 2006).  
 
2.4. DIAGNOSIS OF AIP 
 
Diagnosis of AIP is based on the combination of clinical and biochemical findings at the 
symptomatic phase. During the asymptomatic phase the diagnosis can be established by 
biochemical findings or DNA analysis (Kauppinen, von und zu Fraunberg 2002). 
 
2.4.1. Clinical criteria 
 
The clinical criteria of an acute attack include the paroxysmal nature of the symptoms with 
abdominal or back pain associated with one or more signs of autonomic dysfunction, 
hyponatraemia, muscle weakness or mental symptoms (Mustajoki, Nordmann 1993) (Figure 5). 
 
2.4.2. Biochemical findings 
 
2.4.2.1. Urine analysis of porphyrins and their precursors 
 
The biochemical criteria of an acute attack include more than a four-fold increase of urinary 
PBG excretion, which can be detected by a simple Watson-Schwartz  or Hoesch qualitative test 
(Watson, Schwartz 1941; Lamon et al. 1974; Bonkovsky, Barnard 1998). The results should 
always be confirmed by a quantitative measurement of urinary PBG assayed by ion exchange 
chromatography (Mauzerall, Granick 1956), since false positive results in these screening tests 
are possible, especially, if perchloric acid instead of amyl alcohol is used as an exract 
(Bonkovsky, Barnard 1998; Thunell et al. 2000; Deacon and Elder 2001). False negative results 
are also possible, if the urine samples are not sheltered from the light or taken late during an 
acute attack (Bonkovsky, Barnard 1998; Thunell et al. 2000). 
In 85% of the patients with AIP urinary PBG is elevated in remission as well, but at 
least a two-to four-fold increase in PBG excretion is usually observed in patients during an 
acute attack (Kauppinen, von und zu Fraunberg 2002). Urinary ALA is always increased during 
an acute attack and remains increased in 61% of AIP patients in remission (Kauppinen, von und 
zu Fraunberg 2002). Urinary porphyrins are elevated during an acute attack (Lim, Peters 1984). 
In AIP, urinary excretion of uroporphyrins include both I and III isomers. Their levels are 
higher than those of coproporphyrins I and III (Kauppinen, von und zu Fraunberg 2002). 
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2.4.2.2. Plasma porphyrins 
 
In AIP, plasma emission spectrum test with excitation wavelength of 405 nm shows a peak at 
615-620 nm during an acute attack similarly to HCP, which corresponds to elevated plasma 
porphyrins (Deacon and Elder 2001). This is due to porphyrins ability to absorb light at 
wavelength around 400 nm and their emission as red fluorescence at around 600 nm (Moore et 
al. 1987). Of note, it is usually negative in remission (Kauppinen, von und zu Fraunberg 2002). 
Plasma emission spectrum test is used mainly to exclude VP, since it has an unique 624-627 nm 
spectrum because of  protein-associated plasma porphyrins (Poh-Fitzpatrick, Lamola 1976; 
Deacon and Elder 2001). A high-performance liquid chromatography (HPLC)-mass 
spectrometry can be used to measure porphyrin precursors in  plasma (Floderus et al. 2006). 
PBG and ALA levels were 3.1±1.0 and 1.7±0.7 µmol/L in the plasma samples taken from the 
AIP patients in remission (normal range for P-PBG <0.12 µmol/L and for P-ALA 0.38±0.3 
µmol/L) (Floderus et al. 2006), which is one fiftieth to hundredth part of the levels found in 
urine samples (Kauppinen, von und zu Fraunberg 2002). 
 
2.4.2.3. Faecal porphyrins 
 
Faecal protoporphyrin excretion was increased in 47% of 13 patients with AIP during an acute 
attack and in 19 % of 49 patients during remission in a Finnish series (Kauppinen, von und zu 
Fraunberg 2002), but the level of excretion was lower than found in patients with VP (von und 
zu Fraunberg et al. 2002). In two Canadian patients with AIP faecal protoporphyrin was normal 
during remission (Hindmarsh et al. 1999). Faecal coproporphyrin is usually normal both during 
an acute attack and in remission (Kauppinen, von und zu Fraunberg 2002). The high level of 
coproporphyrin III isomer in faeces which vastly exceeds that of coproporphyrin I isomer and 
protoporphyrin, suggests HCP (Kuhnel et al. 2000).  
 
2.4.2.4. Erythrocyte HMBS activity assay 
 
Decreased erythrocyte HMBS activity (Erc-HMBS)  has been found in 84 % of patients with 
AIP (Kauppinen, von und zu Fraunberg 2002). In the variant form of AIP (5-16% of all 
patients) (Whatley et al. 2000; Kauppinen, von und zu Fraunberg 2002), Erc-HMBS is normal 
due to an alternative splicing of the HMBS gene in erythroid cells (Grandchamp et al. 1989). Of 
note, Erc-HMBS should be assayed in remission, since it may be transiently elevated during an 
attack (Kostrzewska, Gregor 1986). Occasionally Erc-HMBS is normal in patients with non-
variant form AIP because of enhanced erythropoesis, e.g. in hypochromic or hemolytic 
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anaemias and hepatopathy (Kostrzewska, Gregor 1986; Thunell et al. 2000). In contrast, it can 
be decreased in non-porphyric individuals with sideropenia (Thunell et al. 2000). 
 
2.4.3. Mutation screening in AIP 
 
DNA analysis is the most reliable method to confirm AIP in the patients and their symptom-free 
relatives (Kauppinen, von und zu Fraunberg 2002). The direct sequencing of the HMBS gene 
(Sanger et al. 1977) is used to identify a mutation in the proband.  After the mutation is found 
restriction digestion or sequencing  can be used whenever available to identify the 
asymptomatic gene carriers among the family members (Kauppinen, von und zu Fraunberg 
2002). The sensitivity of the mutation analysis is 90-100 % (Andersson et al. 1995; Puy et al. 
1997; Whatley et al. 1999; Kauppinen, von und zu Fraunberg 2002).  The sensitivity is limited 
by  mutations, which are lying in intronic or promoter regions and may not be sequenced or by 
incorrect interpretation of sequences (Puy et al. 1997; Whatley et al. 1999). To date 246 
mutations have been reported in the HMBS gene (http://www.hgmd.cf.ac.uk/ac/gene.php?gene 
=HMBS) and thus, the  high allelic heterogeneity of mutations complicates the DNA testing in a 
single patient. 
 
2.5. THE GENOTYPE-PHENOTYPE CORRELATION 
 
2.5.1. In vitro evidence 
 
When six different HMBS mutants were assessed in lymphocytes by solid-based 
minisequencing, the steady-state mRNA levels varied from 5 to 95% of the corresponding wild-
type allele levels (Mustajoki et al. 1997). When the residual activities of 23 different HMBS 
mutants were studied in E.coli or mammalian cell lines, 0-50% variation in the HMBS activities 
could be observed (Chen et al. 1994; Ong et al. 1997; De Siervi et al. 1999; Solis et al. 1999; 
Mustajoki et al. 2000; Ramdall et al. 2000; Edixhoven-Bosdijk et al. 2002). This could suggest 
that the residual activities vary enough to be able to cause variance in the clinical severity of the 
disease. This could be especially important in hepatocytes. The variation of the liver HMBS 
activity has been demonstrated in three patients with AIP (Strand et al. 1970). The HMBS 
activity measured in patients erythrocytes and lymphocytes has been around 50% of the normal 
(Strand et al. 1972; Sassa et al. 1978), which, however,  may not reflect the tissue-specific 
variation of the enzyme activity. Mutations identified also in the patients with AIP and 
compound heterozygosity (p.R167W and p.R167Q) (Beukeveld et al. 1990; Llewellyn et al. 
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1992; Solis et al. 2004) had a relatively high residual activity in COS cells (Edixhoven-Bosdijk 
et al. 2002).  
 
2.5.2. In vivo evidence 
 
In a population-based study which included both symptomatic and symptom-free AIP patients, 
a genotype-phenotype correlation for the mutations p.W198X, p.R173W and p.R167W was 
demonstrated (Andersson et al. 2000). In this study the p.W198X and p.R173W mutations 
caused a more severe disease in comparison with the mutation p.R167W phenotype (Table 6).  
 
Table 6. Comparison of clinical presentation of AIP patients with  p.W198X, p.R173W and 
p.R167W mutations in the Norrland study (Andersson et al. 2000)  
 
Mutation p.W198X p.R173W p.R167W 
Manifest AIP, n 147 5 3 
Total AIP, n 338 10 24 
Penetrance, % 44 50 13 
Mean number (range) of hospital admission 8 (0-140) 4 (1-10) 0.3 (0-1) 
Attacks during the last year, n (%) 35(30) 1 0 
Mean (range) age of the first attack 27 (7-65) 20 (16-27) 35 (19-50) 
Decreased creatinin clearance, n 29 3 1 
Chronic hypertension, n no 3 no 
 
Excretion levels of porphyrin precursors in two patient groups (p.W198X and p.R167W) 
including both latent and manifest patients did not differ significantly. This study included no 
information on Erc-HMBS activities among the patients. 
The results of a genotype-phenotype correlation in other acute porphyrias have been  
controversial (Whatley et al. 1999; Lamoril et al. 2001; von und zu Fraunberg et al. 2002).  The 
series of VP and HCP patients suggested the absence of a genotype-phenotype correlation 
(Whatley et al. 1999; Lamoril et al. 2001) but they included mainly symptomatic probands. 
Thus, the penetrance rate in these families could not be calculated. Moreover, all the missence 
mutations and splice defects were pooled independent of the affected residues and the 
biochemical findings were not analysed.  
In the Finnish series of VP patients a milder clinical and biochemical disease could be 
demonstrated in the patients with the mutation p.I12T when they were compared to the patients 
with  the mutation p.R152C or c.338G>C (von und zu Fraunberg et al. 2002).  The mutation 
p.I12T was originally identified in a sample from a homozygous patient (I12T/I12T). Of 12 
heterozygous family members with this mutation, only one experienced acute attacks during her 
life span. The attacks were triggered by sulphonamides and barbiturates. This mutation and 
other ones identified in patients with VP and compound heterozygosity, had residual enzymatic 
activities in vitro (Roberts et al. 1998), which explains the survival of the patients and supports 
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an idea of a milder phenotype in some of the mutations in acute porphyrias. 
 
2.6. PATHOGENESIS OF NEUROLOGICAL MANIFESTATIONS IN AIP 
 
2.6.1. Main hypotheses 
 
Despite the progress in understanding of the molecular genetics and biochemistry of AIP, the 
pathogenesis of transient neurological impairment is still obscure (Meyer et al. 1998). 
Currently, two main hypotheses have been raised  (Figure 6). Neurological manifestations of 
acute porphyria could be precipitated either by direct neurotoxicity of porphyrin precursors or 
by deficiency of neural haem-containing enzymes or by both factors together.  
 
2.6.1.1. Neurotoxicity of porphyrin precursors in vitro 
 
The results from the experimental data support the direct neurotoxicity of ALA. In vitro 
conditions, ALA concentrations of 10-5 -10-2 M have been toxic to neuromuscular, muscular and 
spinal cord preparations in animals and cultured neural and glial cells of chicken embryos 
(Loots et al. 1975; Percy et al. 1981; Cutler et al. 1990; Meyer et al. 1998), but not to human 
spinal cord neurons (Gorchein 1989) (Figures 5, 6). In rat brain cortex membrane preparations, 
substantial decrease in Na+K+ATPase activity has been demonstrated after exposure to ALA 
(Russel et al. 1983). Neurotoxicity of PBG has not been tested in vitro (Meyer et al. 1998). 
In rat brain preparation of purified synaptosomes, GABA and glutamate release was 
affected by ALA in a dose dependent manner (Brennan, Cantrill 1981). This could be explained 
by the structural similarity of ALA and inhibitory neurotransmitters GABA and glutamate 
(Brennan, Cantrill 1981). The loss of inhibitory effect of those neurotransmitters due to 
increased ALA levels could be responsible for seizures during an acute attack (Meyer et al. 
1998).  
Increased free radical formation due to enolisation and auto-oxidation of ALA have  
caused damage to proteins and lipids in isolated liver mitochondria and rat brain tissues 
(Demasi et al. 1996). The pathogenetic application of free radicals originating form circulating 
porphyrins has previously been suggested for cutaneous porphyrias (Poh-Fitzpatrick 2000) and 
other neuropathies (Smith et al. 1999; Pop-Busui et al. 2006). 
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Excess of porphyrins and their precursors   
(ALA, PBG) from the liver into circulation 2 
Critical deficiency of haem and haemoproteins in the liver2 
or/and neural tissues 3 
• Direct neurotoxicity of ALA 
      (abnormal functioning or cell death)1 
• Structural similarity of ALA and GABA/glutamate 
      (partial GABA/glutamate receptor antagonism)1 
• Inhibition of Na+/K+ ATPase1 
• Formation of free radicals and reactive oxygen species from 
ALA1.2 
• Deficiency of oxidative chain enzymes (cytochromes type a, b and c) 3 
• Deficiency of nitric oxide synthase 3 (vasospasm)  
• Deficiency of hepatic tryptophan dioxygenase (excess of serotonin 2)   
• Deficiency of cytochrome p450, main inactivator of different 
metabolites, including neuroactive mediators in CNS 4 
• Deficiency of haem-dependent soluble guanilatcyclase 3 (abnormal 
cellular signaling) 
Precipitating 
factors
Partial deficiency 
of HMBS 
1) Direct induction of ALAS12 
2) Increased haem utilisation, 
induction of haem oxygenase2 
 (Indirect induction of ALAS1)
1 Evidence in vitro  
2 Evidence in vivo  
3 Experimental data does not prove this hypothesis 
4 Evidence in liver, but not assayed in neural tissues 
  NEUROLOGICAL MANIFESTATIONS OF AN  ACUTE ATTACK 
Protracted critical deficiency 
of hepatic HMBS 2  
 
Disruption of blood-brain 2 and blood-nerve barriers 
Figure 6. Pathogenesis of neurological impairment during an acute attack of AIP (Main hypotheses) 
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2.6.1.2. Porphyrin precursors in vivo 
 
Excess of ALA itself is not sufficient to explain neurological manifestation in acute porphyrias. 
An injection of ALA at concentrations comparable with the levels measured in 
patients during an acute attack has caused no clinical manifestations in a healthy volunteer, 
“healthy” mice, or patients with neuroblastoma, who have received ALA as an agent for 
photodynamic therapy (Dowdle et al. 1968; Edwards et al. 1984; Mustajoki et al. 1992b; Fukuda 
et al. 2005). Moreover, 61% of AIP patients in remission have increased levels of ALA with no 
symptoms of neuropathy (Kauppinen, von und zu Fraunberg 2002), although mild subclinical 
neuropathy in those patients cannot be excluded.  
 
2.6.1.3. ALA neurotoxicity and physiological barriers 
 
Because blood-brain barrier protects the brain (Bradbury 1979), concentration of ALA in CSF 
is significantly lower (10-100 fold) than measured in serum, which has been shown in the 
healthy individuals and in compound heterozygous HMBS(-/-) mice (Figure 7) (Percy, Shanley 
1977; Gorchein, Webber 1987; Meyer et al. 1998).  
In the concentration of ALA lower than 10-6 M only concurrent agonism of GABA 
autoreceptors could be demonstrated in rat brain synaptosomes (Brennan, Cantrill 1981; Meyer 
et al. 1998). 
 
concentration 
ALA (M) 
   
10-2 
 
10-3 
  Increased parameters of 
oxidative damage in 
nervous tissues 
   
    
10-4   
   
2 x 10-5 
 Direct neurotoxicity in  
animal preparations and 
cultured neural and glial  
cells  
Modification of  uptake 
and efflux of  GABA and  
glutamate  
10-5     in serum 
3 x 10-6   
No symptoms in a  
healthy volunteer 
in serum,  
 
in peripheral  
nerves 
10-6  
Inhibition Na+/K+ 
ATPase in rat brain 
cortex membrane   
 in peripheral 
nerves in CSF 
10-7     in CSF  
    Remission             Attack  Experimental data 
  AIP patients, HMBS (-/-) mice 
 
Figure 7. Comparison of ALA concentration detected in experimental models and AIP patients 
during an acute attack  
 
A blood-nerve barrier, which protects peripheral nerves, is less resistant to toxins than 
blood-brain barrier (Bradbury 1979). In mice ALA concentration in the perineural fluid is about 
30% of that found in the serum (Meyer et al. 1998), which favours ALA neurotoxicity also for 
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peripheral nerves. The concentration of ALA in CSF has been measured in only three AIP 
patients during an acute attack: 192 nmol/L (Gorchein, Webber 1987), 2.1 μmol/L (Sweeney et 
al. 1970) or 35 μg/L (Percy, Shanley 1977). Disruption of the blood-brain barrier, which can be 
seen as reversible multifocal oedema on brain MRI (FLAIR, DW) in patients with AIP during 
an acute attack (Utz et al. 2001; Celik et al. 2002; Yen et al. 2002; Engelhardt et al. 2004; 
Wessels et al. 2005) could result from the permeability failure caused by a transient increase of 
ALA or other currently unknown factors in the circulation and the actual concentration of 
porphyrin precursors in the brain tissue could be higher. 
 
2.6.1.4. Deficiency of haemoproteins 
 
An established mouse model for AIP (Lindberg et al. 1996), resembles the human disease to 
some extent. Compound heterozygous HMBS (-/-) mice have ~30% of the normal HMBS 
activity and develop increased levels of plasma and urinary ALA and PBG only after induction 
of the hepatic ALAS by phenobarbital. Clinical manifestations such as acute attacks do not 
develop in mice. In contrast, chronic neurological deficits could be observed in mice even in 
the absence of biochemical abnormalities (Lindberg et al. 1996). This suggests that haem-
deficiency could play a role in chronic neuropathy in these mice.   
In the brain homogenates of the HMBS (-/-) mice, which have been  decapitated after 
induction of ALAS with Phenobarbital, a CYP2A5 inhibitor, the activity and mRNA expression 
of haem-containing enzymes such as nitric oxide synthase I and soluble guanylate cyclase was 
normal (Jover et al. 2000). After infusion of β-naphtoflavone, a CYP 1A1 inhibitor, the haem-
content in the mice brain was not affected, but the CYP 1A1 enzyme has partly retained in the 
cytosol instead of endoplasmic reticulum (Meyer et al. 2005). The potential application of these 
findings in humans is unclear. The activity of other haemoproteins in neural tissues has neither 
been studied in rodents nor in humans. 
There have been few as well as controversial reports of mitochondrial respiratory chain 
enzymes in muscle tissues. In 15 patients’ samples with “active” acute porphyria, cytochrome c 
oxidase activity was decreased (Goldberg et al. 1985), but in a homozygous AIP patient 
activities of “mitochondrial respiratory chain enzymes” were normal (Solis et al. 2004).  
In 12 patients with AIP during an acute attack, a two-fold increase in the levels of the 
whole blood serotonin (5-hydroxytryptamine, 5-HT) and total plasma tryptophan was found (Puy 
et al. 1993). This could be attributed to the decreased activity of haem-containing hepatic 
tryptophan pyrrolase, as it has been decreased in experimental model of normal rats after 
simultaneous treatment with phenobarbital which stimulates hepatic ALAS1 and dicarbethoxy-
dimethyl-ethyl-dihydropyridine which is a suicide inhibitor of hepatic CYP450 (Litman, Correia 
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1985). Since the clinical picture of carcinoid or serotonin syndrome (Alam 1994) has only little 
similarities with acute porphyria, it cannot explain all symptoms of porphyria (Meyer et al. 
1998).  Deficiency of other hepatic haem enzymes (mainly CYP450) has been demonstrated both 
in patients with acute porphyria and HMBS(-/-) mice (Mustajoki et al. 1994; Jover et al. 2000), 
but their direct role in neurological manifestations of acute porphyria is unclear. 
 
2.6.2. Pathogenesis of autonomic dysfunction 
 
The course of an acute attack is probably directly related to the permeability of blood-brain and 
blood-nerve barriers to porphyrin precursors, which are small size molecules (Kauppinen 
2005). Absence of a barrier for autonomic nerves and a sparse blood-brain barrier in 
hypothalamus and limbic areas may explain initial manifestations of an attack such as 
dysautonomia and mild mental changes. Vagus nerve demyelination, axonal loss and 
chromatolysis of sympathetic ganglion cell in autopsies  (Baker, Watson 1945; Gibson, 
Goldberg 1956; Suarez et al. 1997) support the direct involvement of autonomic fibers and 
explain some of dysautonomic features. 
The growing knowledge of diverse signaling molecules and their receptors in 
autonomic nervous system (Grundy, Schemann 2006) suggests that the mechanisms underlying 
autonomic dysfunction are very complicated. Direct gut-spasmodic effect of ALA (Cutler et al. 
1991) could be mediated through some of the recently recognised receptors. Elevated urinary 
and blood tryptophan metabolites in AIP patients during an acute attack (Puy et al. 1993) and in 
remission (Bonkovsky et al. 1991) and decreased melatonin production in women with 
recurrent acute attacks (Puy et al. 1993) suggest the alteration of tryptophan metabolism in 
acute porphyria. The role of peripheral 5-HT3, 5-HT4 and 5-HT7  and 5-HT1A receptors in gut 
(Grundy, Schemann 2006) and bladder motility (D'Agostino et al. 2006) has been reported, and 
thus, the abnormal tryptophan metabolism could partly contribute to the symptoms of AIP 
(Meyer et al. 1998). 
Abdominal pain is also considered to be the sign of autonomic dysfunction (Meyer et al. 
1998) due to splanchnic dysfunction (Laiwah et al. 1985) such as intestinal dilatation (Berlin, 
Cotton 1950) or spasm (Cutler et al. 1991). The alternative mechanisms such as local 
vasoconstriction and intestinal ischemia have also been suggested (Denny-Brown, Sciarra 
1945; Lithner 2000).  The exact mechanism of pain is still obscure (Laiwah et al. 1985) and 
even enteric ganglionitis/ganglionopathy (Grundy, Schemann 2006) or sensory neuropathy 
could  play a role. 
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2.6.3. Pathogenesis of peripheral neuropathy 
 
2.6.3.1. Neurophysiological studies 
 
Traditionally porphyric neuropathy is considered to be axonal (Kasper et al. 2005). 
Surprisingly, this generally accepted view is based on scarce evidence. Electrodiagnostic studies 
have been reported in a total of 39 patients during an acute attack, and they have been mainly 
single case reports (Table 7). In only half of the 39 patients quantitative measurement of 
porphyrin precursors was performed (Flugel, Druschky 1977; Albers et al. 1978; Wochnik-Dyjas 
et al. 1978; Barohn et al. 1994; King et al. 2002) and only one had AIP confirmed by DNA 
analysis (King et al. 2002) suggesting that some of these cases may not have had acute 
porphyria. In Ridley's classical work (Ridley 1969), only two of 25 patients underwent 
"electromyographic" studies. In one of the cases nerve conduction studies had been performed 
but no numerical values were mentioned (Ridley 1969). 
Eighty one patients have been studied in remission (Maytham, Eales 1971; Mustajoki, 
Seppalainen 1975; Flugel, Druschky 1977; Wochnik-Dyjas et al. 1978; Albers et al. 1978; 
Kochar et al. 2000), and of those, three also at the symptomatic phase (Table 7).  
Axonal abnormalities confined to motor nerves with sparing of sensory fibers were 
common (Albers et al. 1978; Albers, Fink 2004). In addition, mononeuritis multiplex (King et al. 
2002) and proximal predilection for denervation (Albers et al. 1978; Wochnik-Dyjas et al. 1978) 
have been mentioned. The higher vulnerability of radial, tibial and peroneal nerves has been 
reported (Flugel, Druschky 1977; Albers et al. 1978; King et al. 2002). Of the five patients 
studied repeatedly every two weeks during the 1st to 7th week, the lowest motor conduction 
velocities (MCV) was found during the 5th week from the onset of the porphyric symptoms 
(Nagler 1971; Albers et al. 1978). 
In several studies, in which axonal motor neuropathy was suggested, the values of 
velocities were significantly decreased (range 25-50 m/s, mean 40 m/s based on numerically 
available data) (Table 7).  Prolonged distal latency (DL) and minimal F-wave latency (FL)  
(Maytham, Eales 1971; Barohn et al. 1994; King et al. 2002), temporal dispersion and 
conduction block (Barohn et al. 1994) have been evident. All above are the features related to 
demyelinating neuropathies. In other series (Ridley 1969; Stein, Tschudy 1970; Albers et al. 
1978; Wochnik-Dyjas et al. 1978), no demyelinating features were present or no detailed 
information was provided.  
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Table 7. Summary of previous nerve conduction studies in patients with different types of acute porphyria 
during an attack 
 
Series No 1   2 3  4 5 6 7   8-14* Nerves 
studied 
Patient No 1 2 3 4 5 6-9 10-13 14  15    16     16-38 
Normal 
values†
 
                 T 1-5 w 18 d 1-5 w > 3 w  ?    2 w 2 mo  ?-4mo  
 Parameters             
MCV 32 28 40 53  52-55 44-45  50 50/49 >54 
А(CMAP)     0.2-8.3   2.5 8.5/9.0 >6.2 
DL      3.0-4.0 5.0-8.0  4.6  <3.8 
median 
nerve  
FL      Normal 
(n=2) 
   37 <26.4
MCV  37 42  37 53-59  47 53 50/52 >54 
А(CMAP)    Low 4.2-11.2   4.4 9.9/7.9 >6.3 
DL     3.5 2.0-3.2     <3.5 
ulnar 
nerve 
FL         34   
MCV 37 25 40 46 n.m. 45-48  37 35‡ 35 >46 
А(CMAP)     0.7-4.8   N‡ 2.3 >4.1 
peroneal 
nerve 
DL      4.3-5.7   N‡  <4.4 
MCV 26  32 38     36 45 >46 
А(CMAP)        N 19 >6.7 
tibial 
nerve 
FL         68  
 
>52 
Sensory nerves n.d. n.d. n.d. n.d. n.d. + (n=4) n.d. n.d.     +   + +10-12  
Followed in remission n.d. n.d. n.d. + died + (n=2) n.d. n.d. n.d.  n.d. ?10  
PBG measured 
quantitatively 
↑ n.d. n.d. n.d. ↑  ↑ ? ?     ↑  ↑ ↑11,12,14 
n.d 8-10,13 
 
 
1 (Nagler 1971) n=4, 2 (Flugel, Druschky 1977) n=1, 3 (Albers et al. 1978) n=4, 4 (Maytham, Eales 1971) 
n=4, 5  (Reichenmiller, Zysno 1970) n=1 6  (Barohn et al. 1994) n=1, 7 (King et al. 2002) n=1, 8  
(Reichenmiller, Zysno 1970)  n=1, 9 (Zimmerman, Lovelace 1968) n=1, 10  (Ridley 1969) n=1, 11 (Stein, 
Tschudy 1970) n=5, 12 (Wochnik-Dyjas et al. 1978) n=12, 13 (Anonymous 1984) n=1, 14 (Defanti et al. 
1985) n=2 
*No numerical values are reported (n=22: decreased MCV or prolonged DL in 6 patients (30%) and A 
(CMAP) usually low. Number of nerves studied <3 or unknown). 
† Gained from healthy controls in our study (Article II). 
‡ Partial conduction block, (peripheral CMAP/distal CMAP) =0.4 and abnormal temporal dispersion (0.14 
in CMAP area, and 0.73 in duration). 
T, duration of an acute attack prior the study; MCV. Motor conduction velocity; А(CMAP), amplitude of 
compound muscle action potential; DL, distal latency; FL, latency of F-wave; n.m. not measurable; n.d. 
not done;  ? no exact information. Empty squares indicate the absence of available data.  
 
 
The sensory nerves during an acute attack were investigated only in a few studies (Table 
7). Two patients with mild sensory symptoms including loss of vibration sense at the toes, had 
decreased sensory conduction velocities (SCV) (34-43 m/s), prolonged sural DL (4.6 m/s) and 
decreased amplitudes of sensory nerve action potentials (2.9-10 μV) in sural and peroneal nerves 
(Barohn et al. 1994; King et al. 2002). Two of  four patients with clinically pure motor PNP in 
another series had also “abnormal sensory evoked potentials” (Albers et al. 1978) which suggests 
that sensory involvement could be more common in acute porphyria than previously estimated. 
The mild decrease of the amplitudes of compound muscle action potential (CMAP) and 
MCVs were demonstrated in AIP patients with PNP in remission (Maytham, Eales 1971; Flugel, 
Druschky 1977; Wochnik-Dyjas et al. 1978; Albers et al. 1978; Kochar et al. 2000). In addition, 
decreased slower motor conduction of the ulnar nerves was present in 25 patients with latent 
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AIP, including two patients who excreted normal amounts of porphyrin precursors (Mustajoki, 
Seppalainen 1975). This might indicate that other factors besides porphyrin precursors may also 
play a role in porphyric neuropathy. 
 
2.6.3.2. Neuropathological studies in peripheral nerves 
 
Neuropathological studies done from sural  biopsies or autopsy material have demonstrated 
demyelination in addition to axonal changes especially in short motor axons. The histological 
changes of axonopathy consisted of axonal swelling, fragmentation and axonal loss (Baker, 
Watson 1945; Cavanagh, Mellick 1965; Perlroth et al. 1966; Ridley et al. 1968; Sweeney et al. 
1970; Wakayama et al. 1975; Anzil, Dozhic 1978; Suarez et al. 1997). Demyelination manifested 
as swelling, beading and patchy irregularity of myelin sheath (Denny-Brown, Sciarra 1945; 
Schwarz, Moulton 1954; Drury 1956; Gibson, Goldberg 1956; Hierons 1957; Tschudy 1968; 
Stein, Tschudy 1970), the gaps of myelin at the nodes of Ranvier (Denny-Brown, Sciarra 1945), 
perineural lymphocytic infiltration (Denny-Brown, Sciarra 1945; Gibson, Goldberg 1956; 
Hierons 1957), and segmental remyelination (Hierons 1957). In many cases those findings co-
existed in the same nerve (Wakayama et al. 1975; Anzil, Dozhic 1978; Thorner et al. 1981; 
Barohn et al. 1994). Some authors have suggested independent axonal and myelin damage 
during an acute attack (Anzil, Dozhic 1978; Barohn et al. 1994), while others have proposed 
either primarily axonal (Cavanagh, Mellick 1965; Di Trapani et al. 1984; Yamada et al. 1984; 
Suarez et al. 1997) or myelin involvement (Denny-Brown, Sciarra 1945; Gibson, Goldberg 1956; 
Hierons 1957) (Table 8). Perivascular exudation has been reported occasionally (Baker, Watson 
1945; Denny-Brown, Sciarra 1945). The presence of chromatolysis in the spinal anterior horn 
cells is considered as the result of antegrade axonal degeneration, better known as "the dying 
back phenomenon" (Baker, Watson 1945; Gibson, Goldberg 1956; Yamada et al. 1984).  
 
Table 8. Findings in peripheral nerve pathological studies in AIP patients with clinical PNP 
 
 Demyelination 
 
n=17 
Axonopathy and 
demyelination 
n=13 
Axonopathy 
 
n=9 
Normal 
 
n=3 
Motor 
and 
sensory 
nerves 
autopsy  
Mason et al. 1933 
Schwarz, Moulton 1954 
Hierons 1957 
Ten Eyck et al. 1961  
Campbell 1963 
Stein, Tschudy 1970 
Baker, Watson 1945 
Denny-Brown, Sciarra 
1945 
Gibson, Goldberg 1956 
Yamada et al. 1984 
Perlroth et al. 1966 
Cavanagh, Mellick 
1965 
Sweeney et al. 
1970 
Suarez et al. 1997 
Defanti et al. 1985 
Hymans Van den 
Bergh et al. 1937 
Löffler 1919 
Hierons 1957 
Sural  
nerve 
biopsy 
Drury 1956 Anzil, Dozhic 1978 
Wakayama et al. 1975 
Thorner et al. 1981 
Barohn et al. 1994 
Trapani et al. 1984  
 
In several reports of patients who died of an acute attack with PNP the autopsied 
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peripheral nerves were considered normal  (Hymans Van den Bergh et al. 1937; Hierons 1957).   
In contrast to the HMBS (-/-) mouse model in which chronic axonal PNP has developed 
even in the absence of elevated ALA and PBG levels in urine (Meyer et al. 1998), the 
homozygous patient with AIP have had evidence of demyelinating PNP, which was confirmed 
both in the neurophysiological and neuropathological studies (Solis et al. 2004).  
 
2.6.4 Pathogenesis of acute encephalopathy 
 
2.6.4.1. Neuroimaging during an acute attack 
 
Brain neuroimaging (MRI or CT) performed in 13 cases during an acute attack (Table 9) showed 
multi-focal symmetrical lesions, which varied in their location (parietal-occipital or frontal-
temporal). They disappear completely or partially within a few months (King, Bragdon 1991; 
Aggarwal et al. 1994; Black et al. 1995; Kupferschmidt et al. 1995; Garg et al. 1999; Susa et al. 
1999; Utz et al. 2001; Celik et al. 2002; Yen et al. 2002; Engelhardt et al. 2004; Maramattom et 
al. 2005; Wessels et al. 2005). These nonspecific findings correspond at best to vasogenic 
oedema resembling posterior reversible encephalopathy syndrome (PRES) (Hinchey et al. 1996; 
Casey et al. 2000). It is believed to be the result of  transient failure of cerebral vascular 
autoregulation causing  leakage of fluid into the interstitium (Eichler et al. 2002). 
 In two cases of porphyric encephalopathy, diffuse cerebral vasospasm has been 
documented by angiography (Black et al. 1995; Maramattom et al. 2005). It resulted in 
irreversible ischemic lesions in the patients. No vasospasm could be detected by conventional or 
MR-angiography in four additional cases (Celik et al. 2002; Yen et al. 2002; Engelhardt et al. 
2004; Wessels et al. 2005). Ischemic foci described in patients with AIP (Lai et al. 1977; 
Kupferschmidt et al. 1995) could be an outcome of irreversibly impaired microcirculation as 
reported previously in other PRES patients (Casey et al. 2000). 
In a patient with AIP diffusion weighted (DW) MRI imaging with apparent diffusion 
coefficient (ADC) mapping supported PRES as a cause of porphyric encephalopathy (Yen et al. 
2002). In contrast to the patients with PRES, location of foci varies in patients with AIP. The 
appearance of foci in frontal and temporal areas could be explained by disruption of sympathetic 
protection during an acute attack in the area supplied by carotid arteries (Beausang-Linder, Bill 
1981; Sze 1996).  Pre-neuroimaging blood pressure was usually increased (Table 9), which 
suggests that  PRES could be secondary to hypertension (Hinchey et al. 1996). It is currently 
unknown, what causes vasogenic oedema during an acute attack. The absence of malignant 
hypertension (>180/100 mm) in the majority of cases (Table 9) favours endothelial toxicity in 
AIP, as it has been demonstrated in patients with eclampsia (Neal et al. 2004). 
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Table 9. Neuroimaging during an acute attack of AIP 
 Signs and symptoms Blood 
pressure 
Na Main location of foci at 
MRI (T2)   
DW CA/MRA/  Follow-up 
(d/w/mo after previous MRI) 
1* Seizures, hallucinations, 
Babinski signs, PNP, AP 
110 _170 
  70   120 
128 
mmol/L 
Frontal, 
parietal (8 d) 
C   10 d: Normal MRI 
Seizures, confusion, PNP, AP n.d.  n.d. No foci, diffuse cortical 
contrast enhancement  
  2 
18 d later: expressive aphasia n.d.  n.d. Parietal (18 d) Sc   
 
 
7 w: Normal MRI 
3* Seizures, amaurosis, PNP Normal n.d Occipital 
 
Sc   6 mo: Mild residual MRI lesions; 
14 d: CT normal 
4 Seizures, amaurosis, visual 
anosognosia, PNP, AP, AD 
170 
100 
n.d Occipital, right 
frontal  
Sc   4 w: MRI minimal improvement, 
no clinical sequels 
5 Seizures, apraxia, confusion, 
AP 
n.d. 121 
mEq/L 
Parietal C  Vasospasm 
(CA and MRA) 
4 d: MRI parietal foci (contrast 
enhancement), normal MRA 
6* Seizures, lethargy, PNP, AP, 
AD 
135 
 75 
94 
mEq/L 
Basal ganglia, 
thalamus, pons 
(35 d) 
Sc, 
Brain
stem  
  10 mo: Residual MRI lesions, 
clinical sequels (dysarthria) 
7† Seizures, amaurosis, 
hallucinations, lethargy, AP 
180 
100 
130 
mEq/L 
Occipital, 
parietal  (1 d) 
C, Sc  Normal Doppler 
sonography 
26 d: Normal MRI (FLAIR) 
1 attack: Amaurosis, cognitive 
dysfunction, headache, AP, 
AD 
180 
100 
n.d Occipital  C, Sc  Normal Doppler 
sonography 
 
 
Died, brain autopsy normal 
8† 
2 attack: Seizures, amaurosis, 
AP, AD 
170 
110 
n.d Frontal, parie-
tal, occipital 
C, Sc ↑(↑ADC)  Normal (CA)  
9 Seizures, stupor, 
hallucinations, PNP, AD 
210 
     140 
121 
mEq/L 
Frontal C  Normal (MRA) 3 mo: Normal MRI, clinical 
sequels (PNP) 
10† Epileptic state, hallucinations n.d. n.d Frontal, para-
sagittal cortex 
C ↑ Normal (MRA) 6 w: Residual MRI lesions, 
no clinical sequels 
11 Seizures, hallucination, 
confusion, headache, AP, AD 
110 _160 
  95   115 
Low Frontal, 
temporal 
Sc Normal Mild vasospasm 
(CA) 
1 w: Residual MRI lesions 
12 Seizures, amaurosis, lethargy, 
PNP, AP, AD 
170 
     110 
n.d. Frontal, 
occipital 
C ↑ Normal (MRA) 10 d: Residual MRI lesions, 
clinical sequels (PNP) 
 
1 (King, Bragdon 1991), 2 (Aggarwal et al. 1994), 3-4 (Kupferschmidt et al. 1995), 5 (Black et al. 1995), 6 (Susa et al. 1999), 7 (Utz et al. 2001), 8 (Yen et al. 2002) 9 (Celik et al. 2002), 
10 (Engelhardt et al. 2004), 11 (Maramattom et al. 2005), 12 (Wessels et al. 2005). 
*Diagnosis of AIP was confirmed by low Erc-HMBS activity. †No information of elevated U-PBG during an acute attack 
DW, diffusion-weighted imaging; ADC, apparent diffusion coefficient; CA, cerebral angiography; MRA, MR-angiography; AP, abdominal pain; AD, autonomic dysfunction; PNP, 
peripheral neuropathy; C, cortical; Sc, subcortical; ↑ signal hyperintensity (MRI), ↓ hypodensive foci (CT) 
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Pontine myelinolysis was described in a patient with AIP after a rapid correction of 
hyponatraemia (Susa et al. 1999). Diffuse demyelination has been revealed in the brain MRI of a 
homozygous AIP patient in early infancy. The findings are compatible with those of 
neurodegeneration (Solis et al. 2004) which underlines the difference in pathogenesis of AIP in 
the heterozygous and homozygous states.  
 
2.6.4.2. Brain autopsies 
 
Brain autopsies, done in the patients with AIP who have died during an acute attack, have 
revealed diffuse changes such as loss of neurons and chromatolysis in the brain cortex  and/or in 
the brainstem (Baker, Watson 1945; Schwarz, Moulton 1954; Gibson, Goldberg 1956; Hierons 
1957; Stein, Tschudy 1970; Lai et al. 1977). The chromatolysis is an unspecific finding for acute 
porphyria and reflects mainly neurodegeneration and axonal loss (McIlwain, Hoke 2005). In a 
patient with severe SIADH (Suarez et al. 1997) and a few others (Stein, Tschudy 1970), axonal 
loss could be demonstrated in the suprachiasmal and preoptic nuclei of hypothalamus.  
Focal perivascular demyelination in the cerebral white matter or cerebellum has been 
described in several patients (Baker, Watson 1945; Denny-Brown, Sciarra 1945; Gibson, 
Goldberg 1956; Hierons, 1957; Ten Eyck et al. 1961). Demyelination in CNS has not been as 
severe or extensive as in peripheral nerves. In one case, the patient had multiple lesions on the 
brain MRI before her death, but her brain necropsy was macroscopically normal and on 
microscopic examination mild gliosis was the only finding (Yen et al. 2002).  
Focal lesions in brain autopsies have been rare. In one case with acute blindness, focal 
lesions could be demonstrated in both occipital lobes (Lai et al. 1977). In a patient with severe 
hypertension during an acute attack, a haemorrhagic lesion in the internal capsule has been 
revealed (Ridley 1969). In a 14-year old boy, who died of an epileptic state during an acute 
attack, multiple cortical ischemic lesions, subcortical haemorrhage and neuroglial and 
endothelial proliferation could be demonstrated in the brain autopsy (Hierons 1957). 
 
2.6.4.3. Electroencephalography 
 
In EEG diffuse wave slowing has been identified in 39 patients during an acute attack (Goldberg 
1959; Ridley 1969; Stein, Tschudy 1970; Aggarwal et al. 1994; Susa et al. 1999; Celik et al. 
2002; Engelhardt et al. 2004). This finding is abnormal but not specific for acute porphyria and 
commonly seen in other metabolic encephalopathies (Moe, Sprague 1994). Twenty-nine patients 
have experienced also epileptic seizures, but no focal or generalised epileptic activity could be 
demonstrated in 16 of them. 
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2.7. TREATMENT OF AN ACUTE ATTACK 
 
2.7.1. Haem 
 
Haem preparations were proposed for the treatment of acute attacks as early as 1978 (Watson et 
al. 1978). Exogenous haem down-regulates ALAS in the liver (ALAS1) (Jover et al. 2000). 
Haem infusions result in biochemical remission, i.e. decreased excretion of porphyrin precursors. 
Biochemical remission lasts usually for a week, which is enough to abolish symptoms of an 
acute attack, if precipitating factors are eliminated (Mustajoki, Nordmann 1993).  
Haemin is isolated and purified from human red cell concentrates. In Europe and South 
Africa, haemin is commercially available as haem arginate (Normosang®, Orphan Europe). In 
Nothern America  it is available as lyophylised haematin (Panhaematin®, Ovation 
Pharmaceuticals Inc), which reconstituted with sterile water before infusion. In Russia, neither 
haem arginate nor haematin are included in the algorithm of the standard treatment because of 
their cost (Idel'son et al. 1992).  
The only placebo-controlled series found insignificant benefit of haem arginate for the 
analgesic requirement, pain score and duration of the hospital stay (Herrick et al. 1989).  
However, the validity of the trial have been questioned (Mustajoki, Nordmann 1993) because of  
the small number of the patients (11 patients treated with haem and 10 with a placebo), a high 
proportion of the patients with PNP in this series (43%), delayed administration of preparation 
(>2 days after admission) and difficulties in arranging a placebo, which resembles haem arginate. 
In an open series of 22 patients (Mustajoki, Nordmann 1993), the patients treated with haem 
arginate recovered more rapidly in comparison with those treated with glucose infusions in 
earlier studies, however, this comparison is lacking the specificity (Goldberg 1959; Ridley 1969; 
Stein, Tschudy 1970; Mustajoki, Koskelo 1976). Safety and efficiency of lyophylised haematin 
was also supported in six open-labeled studies involving over 200 AIP patients (Anderson and 
Collins 2006) 
Haem arginate and lyophylised haematin are usually infused daily for four consequent 
days but the longer course may be required if the symptoms are severe and progressing. The 
therapy should be started without delay (Mustajoki, Nordmann 1993; Anderson and Collins 
2006) 
The reported side effects include mild coagulopathy (Simionatto et al. 1988), 
trombophlebitis (Mustajoki, Nordmann 1993) and anaphylactic shock in one case (Daimon et al. 
2001). Tolerance to haem preparations after repeated infusions has not been reported. 
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2.7.2. High carbohydrate 
 
The treatment of acute attacks with high carbohydrate diet or infusions (300-500g/day) 
was proposed in 1964, since dose dependent administration of glucose was shown to down-
regulate ALAS1 in rodents in vivo (Tschudy et al. 1964) and in vitro in chick embryo liver cell 
culture (Doss et al. 1985). The underlying mechanism has been discovered recently: the glucose 
down-regulates peroxisome-proliferator-activated receptor γ coactivator 1α (PGC-1α), a protein 
which directly induces transcription of ALAS1 (Handschin et al. 2005). The use of glucose is 
limited only to mild attacks (e.g. mild pain, no paresis, seizures or hyponatraemia) according to 
the guidelines for the treatment of an acute attack in the U.S. and South Africa (Anderson et al. 
2005; Hift, Meissner 2005) or if haem arginate or haematin are not available locally. If glucose 
infusions do not result in clinical remission or if an acute attack is severe at the onset, haem 
preparations should be used. In Finland and France all acute attacks severe enough to require 
hospitalisation are treated with haem arginate (Mustajoki, Nordmann 1993). Mild or clearly 
resolving attacks with minor pain or anxiety may be treated symptomatically (Elder and Hift 
2001). 
 
2.7.3. Elimination of precipitating factors and supportive treatment 
 
During an acute attack, all potentially precipitating factors such as drugs and alcohol should be 
eliminated, infections should be treated promptly and (parenteral) nutrition of patients should be 
adequate to avoid fasting (Kauppinen 2005) 
Table 10. Treatment of an acute attack  
 
Signs and symptoms Medications 
I: Specific therapy Haem preparations (3mg/kg/d for 3-4 consequent days)  
II.Symptomatic therapy  
 Abdominal and/or back pain   Opiates iv/im bolus or in severe cases as infusion 
 Tachycardia, arrhythmia Beta blockers 
 Hypertension Beta blockers, clonidine,  
 Constipation Lactulose  
 Vomiting Phenothiazines*, butyrophenones*, lorazepam 
 Urinary retention Urethral catheter 
 Respiratory muscle paresis Mechanical ventilation 
  Pneumonia Antibiotics* except sulphonamides 
 Mental changes   
  Insomnia and/or anxiety Most benzodiazepines* including zopiclone 
  Hallucinations  Phenothiazines*, droperidol, olanzapine 
 Convulsions Correction of hyponatraemia and hypertension, diazepam.  
Gabapentin, levetiracetam if prolonged treatment is needed 
 Hyponatraemia >125 mmol/L: water restriction due to inappropriate 
antidiuretic hormone syndrome (SIADH) 
≤125 mmol/L or patients with seizures or unconscious: 
infusion of saline. Correction ≤12mmol/L/day. Be aware of  
pontine myelinolysis 
 
* The most of medications in the group are well tolerated 
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Symptomatic therapy for pain, hypertension, nausea,  and severe hyponatraemia is 
commonly required (Crimlisk 1997; Johnson, Criddle 2004; Anderson et al. 2005). If a 
hypertensive crisis develops it should be treated as regular (Patel, Mitsnefes 2005). Epileptic 
seizures may be treated with intravenous diazepam, gabapentin or levetiracetam (Crimlisk 1997; 
Zadra et al. 1998; Anderson et al. 2005; Zaatreh 2005).  
 
2.7.4. Future therapies 
 
Recombinant human HMBS preparation has been shown to lower plasma PBG levels in 
symptom-free patients with increased excretion of urinary PBG (Sardh et al. 2003). However, no 
decrease in plasma ALA levels could be demonstrated in these patients. The similar biochemical 
effect of rh-HMBS therapy was demonstrated in the HMBS(-/-) mouse model (Johansson et al. 
2003a). The efficacy evaluation of rh-HMBS-enzyme replacement therapy for acute attacks of 
AIP is currently ongoing (http://www.zymenex.com).  
Both adenoviral mediated and non-viral HMBS gene transfers corrected the metabolic 
defect in the cell lines of AIP patients’ and HMBS (-/-) mice (Johansson et al. 2002; Johansson 
et al. 2003b; Johansson et al. 2004a). Only virus-mediated DNA transfer into the liver was 
successful and corrected metabolic defect in HMBS (-/-) mice at least for a month  
(Johansson et al. 2004a; Johansson et al. 2004b). Adenoviral cytotoxicity especially for  
hepatocytes, the immunological response to viral antigens and only transient transduction of the 
therapeutic gene limit potential applications of this method (Tarner et al. 2004).  
 
2.8. PREVENTION OF ACUTE ATTACKS 
 
Early diagnosis with mutation screening among a patient’s relatives and information about 
precipitating factors can prevent further attacks among patients with acute porphyria 
(Kauppinen, Mustajoki 1992). In remission, patients may tolerate medications classified as 
potentially safe and the small amounts of alcohol but if porphyric symptoms appear their use 
should be restricted (Kauppinen, Mustajoki 1992; Doss et al. 2000). 
The exogenous hormonal therapy such as contraceptive pills was introduced for the 
profilactical treatment of recurrent acute attacks more than 40 years ago (Perlroth et al. 1966) but 
contraceptive pills may provoke acute attacks in 5% of women with AIP (Kauppinen and 
Mustajoki 1992). GnRH analogues are not porphyrinogenic and prevent attacks in a half of the 
women with cyclical symptoms (Anderson et al. 1981; Herrick et al. 1990; De Block et al. 
1999), The responders more frequently had regular menstrual cycles and pronounce decrease in 
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the oestradiol level after the treatment with GnRH analogues (Anderson et al. 1990; Herrick et 
al. 1990; De Block et al. 1999) when compared to the women, who were non-responders or 
responded only to a high dose of the preparation (Anderson et al. 1990; Herrick et al. 1990; 
Soonawalla et al. 2004; Hift, Meissner 2005; Pischik, Kauppinen 2006). This therapy causing 
menopause decreased excretion of porphyrin precursors to 60% of the previous values in both 
groups (Anderson et al. 1990; Herrick et al. 1990; De Block et al. 1999). Cyclical attacks do not 
predict attacks during pregnancy, and pregnancy nowadays seldom precipitates acute attacks 
(Kauppinen, Mustajoki 1992; Andersson et al. 2003). Haem preparations have been used during 
pregnancy without complications (Gorchein, Webber 1987; Hift, Meissner 2005; Pischik, 
Kauppinen 2006). Weekly haem infusions may alleviate the severity of recurrent attacks 
(Kauppinen 2005). The liver transplantation can be an option for a severely affected patient with 
severe recurrent attacks, if the standard treatment was unsuccessful (Soonawalla et al. 2004), but 
to date no long-term follow-up exists.  
 
2.9. PROGNOSIS 
 
Before the glucose and haematin treatment of an acute attack has been introduced, the mortality 
rate was very high (Goldberg 1959; Ridley 1969; Mustajoki, Koskelo 1976). In Waldenström 
series it was 66% among symptomatic patients (Waldenström 1937).  
Currently, because of the improved diagnostics, the early and effective treatment with 
haem preparations and the prevention of acute attacks (Kauppinen, Mustajoki 1992) the 
mortality has decreased to 5-20% of the cases including the cases which were not diagnosed 
previously or in the early phase of an acute attack (Kauppinen, Mustajoki 1992; Jeans et al. 
1996; Hift, Meissner 2005). 
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3. AIMS OF THE PRESENT STUDY 
 
At the beginning of this study in 1995 a few cases only of acute porphyria have been suspected 
clinically over the previous decades in the north western part of Russia including St Petersburg 
area. No systematic clinical and genetical studies have been performed. At that time, very little 
was known about the mechanisms underlying the neurological manifestations during an acute 
porphyric attack. 
 
 
The aims of this study: 
 
1. To identify patients with AIP admitted to the neurological wards in North Western Russia 
2. To study neurological manifestations and a natural course of an acute attack. 
3. To study acute polyneuropathy and central nervous system involvement in patients with AIP 
using electrophysiological techniques and neuroimaging. 
4. To identify gene defects resulting in AIP among Russian patients. 
5. To characterise the outcome of mutations at mRNA and protein level. 
6. To investigate a genotype-phenotype correlation in AIP. 
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4. MATERIALS AND METHODS 
 
4.1. PATIENTS 
 
During 1995–2006, 108 patients with signs and symptoms suggestive of acute porphyria were 
studied prospectively, both clinically and biochemically to exclude or diagnose acute porphyria, 
when they were admitted to the neurological wards in North Western Russia because of 
acute/subacute muscle weakness, seizures or confusion. The patients were selected from the City 
Hospital #2 (the main place of this study), Regional St Petersburg Hospital, Departments of 
Neurology of the Military Medical Academy and Postgraduate Medical Academy, three local 
hospitals in St Petersburg and Pskov Regional Hospital. Most of the patients were admitted as 
acute cases to those hospitals. If acute PNP or other signs suggestive of porphyria were found, a 
neuromuscular specialist from the City Hospital #2 was informed and continued the subsequent 
examination. Data from the medical history was obtained from the hospital records and by 
interviewing each patient. The patients were unrelated and pedigrees were traced three to four 
generations back. Twelve Russian patients were diagnosed with AIP. 
In addition the clinical, biochemical and genetic data of 291 Finnish AIP patients 
diagnosed in 1966-2006 was analysed. Of the Finnish patients, two individuals were diagnosed 
in 2003-2006 at the Central University Hospital of Helsinki and had neurological manifestations. 
Their detailed clinical and neuroradiological data was also included in the study. 
The diagnosis of symptomatic AIP was confirmed by biochemical analyses of haem 
precursors accompanied by typical clinical manifestations (n=14). DNA testing was performed 
later at the symptom-free phase (n=13). After diagnosis of AIP in index case was confirmed, the 
family members were enrolled in the study group in 2000-2005. 
An acute attack was defined as acutely developed typical symptoms of porphyria such as 
abdominal pain and/or autonomic dysfunction in patients with at least four-fold increase of 
urinary  PBG excretion (Mustajoki, Nordmann 1993). Acute PNP manifested as diffuse muscle 
weakness, symmetrically distributed hyporeflexia and sensory loss (McLeod 1995), and was 
attributed to AIP only if evolved during an acute attack.  
Study protocol followed principles outlined in the Declaration of Helsinki and ethical 
issues were approved by the City Hospital #2, St Petersburg, Russia and Central University 
Hospital of Helsinki, Finland. 
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4.2. METHODS 
 
4.2.1. Neurological examination  
 
Neurological examination included quantitative assessment of muscle strength from 0 to 5 in 
upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors and foot dorsal 
flexors according to Medical Research Council (MRC, 1943). Then a MRC sum score was 
calculated with a maximal value of 60 (Kleyweg et al. 1991). Reflexes, tone, sensation, co-
ordination and mental state were evaluated. The intensity of pain was assessed using linear 
Visual Analogue Scale (VAS, 0 to 10 cm, Jensen, Karoly 1992). 
 
4.2.2. Biochemical analysis 
 
During an acute attack the qualitative Watson- Schwartz test detecting urinary PBG (Watson, 
Schwartz 1941), quantitative measurement of urinary ALA (Mauzerall, Granick 1956) and/or 
coproporphyrin (Rimington 1958) were performed in Russia. For the ALA measurement, 
chromatographic columns were manually filled with activated charcoal (Mauzerall, Granick 
1956; Kuznetsova et al. 1981).  
In remission, urinary ALA and PBG were measured using Bio-Rad columns (Bio-Rad 
Laboratories, USA)(Mauzerall, Granick 1956), and urinary and faecal porphyrins using the high 
performance liquid chromatography (HPLC, Varian 9100, Varian Inc., USA)(Li et al. 1986) in 
Porphyria Research Laboratory in Finland. Plasma porphyrin spectrum was assayed using 
spectrofluorometry (Poh-Fitzpatrick, Lamola 1976). The erythrocyte HMBS activity was studied 
using spectrophotometry by measuring the conversion of PBG to uroporphyrin (Ford et al. 
1980).  
 
4.2.3. Neurophysiology 
 
The motor nerve conduction and F-wave studies were performed using standard techniques and 
surface recording (Viking IV, Nicolet, USA)(Livenson, Ma 1992). The sensory response was 
recorded antidromically for sural and orthodromically for ulnar and median nerves using plate-
shaped electrodes. The skin temperature was maintained at > 320. Recorder values were 
considered normal if they were within the mean±2SD of those obtained from control subjects. 
Demyelination was considered if MCV was <70% of the low normal level (LNL), or DL or FL 
were ≥150% of the upper normal level (UNL) (Meulstee, van der Meche 1995). Axonal 
neuropathy was considered if the amplitude of CMAP was ≤50% of LNL in two or more nerves 
(Rees et al. 1995). If the signs of axonal and demyelinating neuropathy co-existed mixed PNP 
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was diagnosed. Electromyography was performed with concentric needle electrodes. Details of 
individuals examined are provided in article II. 
 
4.2.4. Neuroimaging 
 
Computed tomography (CT) of the brain was performed using a single-detector CT (Somaton 
AR.T., Siemens, Germany) in Russia and multidetector CT (LightSpeed 8, GE Medical Systems, 
Wis, USA) in Finland with a contiguous 5 mm slice thickness. 
Magnetic Resonance Imaging (MRI) was performed using standard head coil  (T1 and T2 
weighted, Magneton Impact, Siemens in Russia and T1, T2, fluid-attenuated inversion recovery 
(FLAIR) and diffusion weighted (DW) imaging, Siemens Sonata in Finland). 
 
4.2.5. DNA-analysis 
 
4.2.5.1. Mutation screening  
 
Genomic DNA was extracted from leukocytes using the QIAamp DNA Blood mini Kit (Qiagen 
Inc, Valencia, CA, USA) (Higuchi 1989) and amplified using polymerase chain reaction (PCR) 
(Mullis, Faloona 1987). The primers and PCR conditions are described in the article III. PCR 
fragments were purified using QIAquick PCR purification Kit (Qiagen Inc, Valencia, CA, USA; 
http://www1.qiagen.com) before sequencing (Sanger et al. 1977) with Amplicycle Sequencing 
Kit (Perkin Elmer, Wellesley, MA, USA), or when an ABI3730 Automatic DNA Sequencer was 
used with Sequencing Analysis 5.0 BigDye Terminator version 3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA, USA). Direct sequencing of the HMBS gene was 
performed for all exons and exon-intron boundary regions, except for erythroid-specific exon 2, 
in both directions. The mutation was confirmed by repeated analyses in the presence of negative 
and positive controls if available. Digestion with restriction enzymes was used as an additional 
method to confirm the mutation whenever the appropriate enzyme was commercially available 
(The New England Biolabs, Beverly, MA, USA). 
 
4.2.5.2. mRNA isolation, cDNA synthesis and sequencing 
 
To verify the transcripts of the novel mutations at mRNA level, total mRNA was extracted from 
patients’ Epstein-Barr virus transfected lymphoblastoid cell lines or fibroblasts (Chirgwin et al. 
1979). Complementary DNA was synthesised from 5 μg of total RNA using Superscript II Rnase 
H-Reverse Transcriptase (Gibco BRL Life Technologies, Gaithersburg, MD, USA) and random 
hexamers and directly sequenced as described above.  
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4.2.5.3. Eukaryotic expression of HMBS mutations  
 
The expression of a mutant polypeptide was studied in COS-1 eukaryotic cell lines using SVpoly 
vector (Stacey and Schnieke, 1990). The mutations were inserted in the human HMBS-SV-poly 
(Mustajoki, et al. 2000) using Chameleon double-stranded site-directed mutagenesis kit 
(Stratagene Cloning System, La Jolla, CA, USA) or by ligating mutated RT-PCR fragments into 
the corresponding sites of the HMBS-SV-poly using T4 DNA ligase (New England Biolabs, 
Beverly, MA, USA). The details of mutagenesis primers and plasmid construction are provided 
in article III. Forty eight hours post-transfection crude cell extracts of plasmid-containing 
cultures were lysed with 300 μL of incubation buffer 150 mM Tris-HCl, 1 mM EDTA, 1% [v/v] 
Tween 20 and sonicated three times for 10 sec. The supernatant was assayed for HMBS activity 
(Ford et al. 1980). The enzyme activities obtained were compared to that of the background level 
from COS-1 cells transfected with SVpoly alone. 
 
4.2.6. Statistical analysis 
 
Continuous variables were expressed as the mean ± standard deviation (SD) and analysed with 
Mann-Whitney U-test when two groups were compared or Kruskal-Wallis one-way ANOVA 
when more than two groups were compared simultaneously. The mean ± standard error (SEM) 
was used for a genotype-phenotype comparison. 
To develop a scale for the severity of an acute attack regression analysis with maximum group 
discrimination as optimization criteria (Kendall and  Stuart 1968) was employed to evaluate 
association with outcome variables (the long-term prognosis of a patient) and covariates 
(symptoms and signs of an acute attack). The initial values of covariates were normalised from 0 
to 1, and an equation of α2 =1 resulted in one solution only for each regression coefficient (α). 
Thereafter the scores were adjusted according to αi from 1 to 6. 
For a genotype-phenotype comparison logistic regression with the maximum likelihood 
estimation as optimization criteria was employed to evaluate the association between 
dichotomous outcome variables (the occurrence of acute attacks) and covariates (the mutation, 
gender, age at the time of diagnosis, and the results of biochemical tests). Statistical calculations 
were performed with SPSS version 10.04 and NCSS 2000
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      5. RESULTS 
 
5.1. GENERAL CHARACTERISTICS OF THE PATIENTS  
 (Articles I, II and additional data) 
 
5.1.1. Screening of porphyrin metabolites in the selected patients  
  
Porphyrin metabolites were studied during an acute phase of 108 Russian patients, who had signs 
and symptoms suggestive of acute porphyria. The levels of urinary porphyrins or their precursors 
were normal in 85 cases (79%) (Figure 8).  
Of the 23 patients who had a 1.5-10 fold excretion of urinary porphyrins or their 
precursors 11 individuals were excluded. Exclusion criteria were as follows: less than two-fold 
increase in  urinary PBG assayed by the qualitative method, ALA and coproporphyrin, and 
neurological symptoms, which could be attributed to other diseases (Figure 8).  In seven of them 
porphyrin metabolism was normal by the time of discharge. In two cases, acute porphyria could 
not be excluded during an acute phase because of constant coproporphyrinuria (two to three-
fold). During the six months follow-up urinary excretion of coproporphyrin normalised and other 
diagnoses could be established (Figure 8). In summary, of the selected patient group attending 
acute neurological wards, 12 cases (11 %) were diagnosed with acute porphyria indicating that 
screening for porphyrin metabolites, especially urinary PBG is essential.  
 
5.1.2. Characteristics of the patients with AIP 
 
All Russian patients with acute porphyria were diagnosed to have AIP (Table 10). They were 
female patients and had signs of autonomic neuropathy and mental symptoms before developing 
paresis or seizures. By the time of admission, ten patients experienced severe acute PNP, one 
patient had generalised seizures and mild fever, and the other had hypertensive crisis with 
vertigo and mild cognitive impairment. PNP was recurrent with 13 and 20 months interval in two 
cases.  
None of the patients were diagnosed with AIP before they developed signs of 
neurological deficits. Of the 12 patients, seven experienced numerous short episodes of mental 
lability, abdominal pain, palpitations and constipation, which varied from mild to moderate. This 
symptomatic but undiagnosed period lasted up to 19 years (mean four years). Before acute 
porphyria was confirmed, the patients were misdiagnosed with various diseases (Table 12).  
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108 patients with signs and symptoms suggestive of acute porphyria  
Inclusion criteria: acute/subacute PNP and/or seizures and/or acute/subacute cognitive impairment + 
autonomic dysfunction and/or abdominal/back pain 
    
  
Urinary PBG and coproporphyrins measured during acute symptoms:  
 
 
 
 
    
Elevated             Normal 
  
 
   
23 patients                                                85 patients 
Patients with Guillain-Barré syndrome (GBS), who manifested with pain >5 VAS 
and /or dysautonomia     
               axonal PNP according to the nerve conduction studies 
PNP of other origin (alcoholic, non specified) 
Acute thallium intoxication (PNP, autonomic dysfunction, abdominal pain, coma) 
Polymyositis 
Systemic lupus erythematosus (mild PNP, dysautonomic features and myalgia) 
Hyperthyroidism (+ PNP) 
Botulism (vomiting, acute flaccid tetraparesis, blurred vision, diplopia, bulbar signs) 
Multiple compression neuropathy 
Epilepsy  
Somatoform disorder  
Schizophrenia 
The diagnosis was not verified  
Not followed 
   N 
34
4
5
1
2
1
1
1
1
15
5
3
6
10
 
 
 
 
    
Urinary excretion of ALA and PBG, urinary and faecal porphyrins, plasma porphyrin spectrum, and Erc-HMBS 
in remission 
  
 
  
Abnormal                 Normal* n=11 
 
 
 
 
   
                                               
11 patients (5 men, 6 women) 
  
The cause of porphyrinuria Neurological manifestation N 
 
12 patients  
with acute 
porphyria 
(12 women) 
  
 
 
 
12 patients 
with AIP  
 
 
 Primary biliary cirrhosis      
Autoimmune hepatitis. Hemolytic 
anaemia. 
Systemic vasculitis. Acute hepatitis B   
Alcohol intoxication 
 
     
  + and hepatitis C              
Alcohol abuse and liver cirrhosis           
      +suprarenal insufficiency      
 A drug-induced hepatitis in a patient 
with schizophrenia             
The cause of porphyrinuria and 
neurological manifestations remained 
unknown                                            
Chronic autonomic dysfunction, acute PNP 
Autonomic dysfunction, subacute PNP, 
abdominal pain 
Recurrent PNP, dysautonomia, pain 
Subacute PNP, myalgia 
Acute lumbosacral plexopathy and abdominal 
pain due to trauma 
Acute PNP, encephalopathy, rhabdomyolysis 
Subacute/recurrent PNP, autonomic 
dysfunction, mental symptoms, muscle pain 
Chronic psychosis, muscle pain and 
weakness 
Subacute PNP, encephalopathy, psychosis 
(n=1), subacute PNP with pain (n=1), acute 
idiopathic PNP + dysautonomia (GBS?) 
1 
 
1 
1 
1 
 
1 
1 
 
1 
 
1 
 
 
3 
 * Except for mild elevation of urinary coproporphyrin in two cases (primary biliary cirrhosis and hemolytic 
anaemia)  
 
Figure 8. Graphic presentation of the patients screened for urinary porphyrins and their precursors to 
exclude the diagnosis of acute porphyria during the period of 1995-2005 years 
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Table 11. Clinical characteristics of AIP patients 
 
Pt* Sex Age at the 
onset of 
porphyria 
(years) 
Number of 
attacks 
before the 
diagnosis 
Age at the 
time of the 
diagnosis 
(years) 
Duration of autonomic 
impairment and mental 
symptoms before the 
appearance of  neurological 
manifestations  (d) 
Neurological 
manifestations at 
presentation 
1 F 35 1 36 6/14† PNP¶ 
2 F 23 9 34 10 PNP 
3# F 36 - 36 21 PNP¶ 
4# F 20 7 22 29 PNP 
5 F 17§ >20 29 15 PNP¶ 
6 F 57 - 57 7 PNP¶ 
7 F 18 - 18 18 PNP¶ 
8 F 23 - 23 3 Seizures and lethargy 
9 F 23 4 26 5  PNP 
10 F 53§ - 53 15 PNP¶ 
11 F 24 3 24 12‡/10 PNP 
12 F 25 3 25 3 Vertigo 
13 F 17 >10 36 10 Rhabdomyolysis, SIADH 
14 F 23 1 24 6 Seizures and lethargy 
Mean 28  32 11.5  
F, female; PNP, peripheral neuropathy 
*Cases 1-12 were diagnosed in Russia, cases 13 and 14, in Finland.  
† Diagnosis was confirmed during the patient’s second attack with PNP  
‡ Although the diagnosis of AIP was confirmed during the patient’s first attack with PNP, the patient experienced a 
second attack with PNP 
§ Family history of a deceased relative resembling acute porphyria  
¶ PNP confirmed by nerve conduction studies  
# Died during an acute attack 
 
Table 12. Misdiagnoses in patients with AIP before the diagnosis of acute porphyria was suggested 
 
I. Before the appearance of neurological deficits 
 A. Psychiatric diseases 
 Hysteria 
 Schizophrenia 
 B. Gastroenterological and nephrological conditions 
 Acute gastritis 
 Acute hepatitis 
 Irritable bowel syndrome 
 Acute pyelonephritis 
 Acute interstitial nephritis 
 Bartter’s syndrome 
 Primary SIADH 
 C. Surgical emergencies 
 Bowel obstruction 
Paralytic ileus  
Renal colic 
Acute cholecystitis 
D. Miscellaneous 
 Hypertensive crisis 
Acute poisoning  
Acute adnexitis  
Familial Mediterranean fever 
Hyperthyroidism 
II . After the neurological deficits manifested 
 Guillain-Barré syndrome 
 Acute polymyositis 
 Hypokalaemic paralysis 
 Acute viral/toxic encephalitis 
 Epilepsy 
 Hypertensive encephalopathy 
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Family 1 
Family 2 Family 3 Family 4 Family 5 
Family 6 Family 7 Family 8 Family 9 
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Family 10 Family 11 Family 12 
Family 13 Family 14 
Figure 9. AIP pedigrees. Black circle and square = affected female and male with clinically symptomatic disease. Grey circle/square = 
asymptomatic female and male carrying the affected gene. Open circle/square =clinically  unaffected family members. M+ = mutation-
positive; M- = mutation-negative. Open circle/square without M -=not tested with DNA-analysis, but no suggestive information of AIP 
according to a medical history. ? = acute porphyria is possible according to a medical history. Arrow = proband 
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5.2. BIOCHEMICAL ANALYSES 
   (Article I, II and additional data) 
 
5.2.1. Porphyrins and their precursors 
 
An acute attack was diagnosed using a qualitative test of PBG in all Russian patients, but 
increased excretion was confirmed by a quantitative test in remission performed in Finland 
(Tables 13 and 14).  Urinary ALA and coproporphyrin were increased during an acute attack. 
The quantitative measurements for urinary coproporphyrins and ALA are not standardised in 
North Western Russia, and thus, the levels of ALA remained at the low range compared to 
those in Finland due to methodological differences. The quantitative analysis for urinary 
PBG was not available in Russia. 
 
Table 13. Biochemical findings of urinary porphyrins and their precursors during an acute attack  
 
Pt ALA PBG Coproporphyrin 
 
 
Day of  the 
measurement from 
the onset of an 
acute attack 
<9.9 
μmol/L* 
qualitatively 
-/+/++/+++‡ 
< 64 
nmol/g 
creat# 
<320 
nmol/L# 
1 17 19.6 +++ 282  
 31 n.d. +++ 216  
2  11 n.d. +++  3000 
3 46 n.d. +++ n.d.  
4 41 22 +++ 157  
5 25 60 +++ 879  
6 11 n.d. +++ 360  
 28 10.3 +++ 94  
7  25 n.d. +++  583 
 31 n.d. +++  3262 
8 8 n.d. +++ n.d.  
 13 10.3 +++ 110.4  
9  8 26.1 +++ 183  
10 50 42 +++ 431  
 57 101 +++ 141  
11  7 n.d. +++  1154 
12 6 14.4 +++ 24.5  
Performed in Finland  <34 
μmol/L† 
<9 μmol/L§ <230 nmol /L** 
13 16 n.d. 790 730  
 23 340 630 n.d.  
14 12 310 310 170  
 
*Chromatographic columns were manually filled with activated charcoal (Kuznetsova et al. 1981). 
†Measured using Bio-Rad columns (Bio-Rad Laboratories, USA) (Mauzerall, Granick 1956). 
‡(Watson, Schwartz 1941). §Measured using Bio-Rad columns (Mauzerall, Granick 1956). 
#(Rimington 1958). **(HPLC, Li et al. 1986).  
 
In remission, the mean urinary level of PBG was 40-fold compared to the upper normal 
level, ALA 6-fold, coproporphyrin 3-fold and uroporphyrin 70-fold, respectively (Table 14). 
Faecal excretions of porphyrins were within the normal range but plasma porphyrin spectrum 
was usually positive.  Two patients (cases 3 and 4) died during an acute attack and no 
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measurements of PBG or ALA in remission could be done. The erythrocyte HMBS activity 
was decreased in the children of case 3 (40 and 39 pmol uroporphyrin/mg prot) and the 
mutation, which was found in the HMBS gene, confirmed the diagnosis of AIP in this family. 
In case 4 excretion of PBG, ALA  and coproporphyrin  were increased even after 41 days 
from the onset of an acute attack. The diagnosis of AIP in her case could not be confirmed 
because the enzyme activity was not measured and her relatives were not available. Severe 
symptoms of acute porphyria, absence of the skin lesions and markedly elevated urinary 
PBG excretion even two weeks from the onset of an acute attack made the diagnosis of AIP 
the most likely. 
 
Table 14. Biochemical findings of abnormal haem metabolism among patients with AIP in remission 
 
  Erythrocyte* 
 
 Urine* Faeces* Plasma  
 
 
 
Pt 
 Erc-HMBS 
(55-100 
uroporphyrin/
mg prot) 
 ALA 
(<34 
μmol/L)  
PBG 
(<9 
μmol/L)
Copro-
porphyrin
(<230 
nmol /L) 
Uro-
porphyrin
(<36  
nmol /L)  
Copro-
porphyrin 
(<100 
nmol/g) 
Proto-
porphyrin
(<130 
nmol/g) 
Emission 
max  
619 nm 
1   37  124 293 287 2904 n.d. n.d. + 
2    39  122 205 701 1111 18 22 + 
5   58  326 523 812 5485 n.d. n.d. + 
6   42  173 297 915 1573 n.d. n.d. + 
7    32  511 632 258 10955 11 22 + 
8   45  148 258 977 1498 26 35 + 
9    42  209 795 986 2754 n.d. n.d. + 
10   47  97 187 480 1198 n.d. n.d. + 
11    53  305 1012 526 3093 34 18 + 
12   43  110 114 246 1418 n.d. n.d. + 
13   77-81†   150 300 270 1900 1 2 + 
14   39  130 250 130 1200 n.d. n.d. - 
Mean 46  200 406 549 2924 18 20  
 
*Based on one analysis in each patient.  
†Range based on three measurements.  n.d., not done 
 
5.2.2. Other biochemical findings 
 
The elevation of serum liver transaminases was the most common finding (Table15).  If a 
patient had paresis or seizures (i.e. a severe attack) hepatopathy was commonly present.  
Leukocytosis, elevation of serum creatinine and hyponatraemia were also frequent during an 
acute attack (Table 15). CSF analyses were within the normal range in 13 patients examined 
during an acute attack. 
During the subsequent acute attacks in eight patients the elevation of transaminases 
was uncommon since they were treated in the early phase of an acute attack. In remission, 
mild elevation of transaminases persisted in one patient only who had chronic hepatitis C. 
During the follow-up serum creatinine values were constantly elevated in one patient 
with monthly recurrent attacks (up to 136 μmol/L, Table 15) and in another patient with 
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interstitial nephritis. Her renal failure was multifactorial (recurrent acute attacks, 
hypertensive crises during an acute attack and use of gentamycin). Currently she needs 
weekly haemodialysis similar to her sister. In her sister’s case renal insufficiency developed 
after an acute attack three years before the diagnosis of AIP was established by a pedigree-
analysis and DNA testing.  Their mother is a symptom-free patient with AIP. Father had 
several hypertensive crises and died of myocardial infarction at the age of 47. Thus, the 
siblings have probably inherited other, currently unknown factors, which made patients 
vulnerable for hypertension and renal failure. 
 
Table 15. Biochemical findings among AIP patients with neurological manifestations  
during an acute attack 
 
 Abnormal values 
 of 16 
attacks* 
% 
attacks
Range of 
abnormal values 
 
Normal range 
I. Blood smear      
 Leucocytosis 
(with no signs of infection) 
7 44 10.6-19.2  > 10x106/L 
 Hypochromic anaemia, Hb 5 31 9.2-11.9 g/dL  12-14.5  g/dL 
II. Serum biochemistry      
 ALT 16 100 46-269 U/L  < 40 U/L 
 AST 14 88 41-601† U/L  < 35 U/L  
 Creatinine 5 31 113-152 µmol/L  55-110 µmol/L 
 Urea  5 31 8.9-18.3 mmol/L  1.7-8.3 mmol/L 
 Bilirubin 3 19 42-70 µmol/L  8.5-20.5 µmol/L 
 Creatine kinase 5‡ 31 254-21806 U/L  <190 U/L 
 Sodium 9 56    
     low 8 50 108-129 mmol/L  135-155 mmol/L 
     high 1 6 156 mmol/L  135-155 mmol/L 
 Potassium 5 31    
     low 4 25 2.6-3.4 mmol/L  3.5-5.6 mmol/L 
     high 1 6 5.8 mmol/L  3.5-5.6 mmol/L 
 Calcium ionised 1 6 0.88 mmol/L  1.05-1.3 mmol/L 
 Creatine glomerular filtration 3 19 29-77 mL/min  100-160 mL/min 
III. Urinalysis      
 Leucocytes 6 38   negative 
 Erythrocytes 3 19   negative 
 
* Here and below 16 acute attacks are analysed, since two of the Russian patients experienced acute 
attacks with severe neurological manifestations twice 
† Range 41-103 U/L, if a patient with rhabdomyolysis is excluded 
‡ Not measured in four acute attacks, of those one patient had severe myalgia 
 
5.3. CLINICAL MANIFESTATIONS DURING AN ACUTE ATTACK 
(Articles I,II and additional data) 
 
5.3.1 A case report of acute porphyria with neurological symptoms  
 
A 26-year-old Russian woman (case 5) who was admitted to a neurological ward  because of 
acute sensorimotor PNP accompanied by abdominal and back pain, tachycardia, 
constipation, hallucinations and depression (Pischik, Kauppinen 2006). She had had 
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recurrent attacks of severe abdominal pain in premenstrum during two years, which started 
after her first delivery. She was treated as a hysteric patient receiving anti-depressive drugs 
and tranquilizers with no effect.  
The acute attack started 27 days before the admission to the neurological ward with 
abdominal and back pain, constipation and tachycardia. Surgical aetiology was excluded. 
Twelve days later muscle weakness manifested as monoparesis in the right arm, mainly as 
radial nerve palsy, but pareses became diffuse within a week. By the time of admission, her 
muscle weakness was symmetrical affecting both the upper and lower extremities (MRC 
sum-score 40). Facial diplegia, hyporeflexia and neuropathic sensory loss were evident.  
The blood tests demonstrated mild elevation of serum transaminases and creatinine 
levels. Her urine was pink and became dark when exposed to the light.  Haem arginate was 
started for four days together with tramadol, chlorpromazine and propranolol. Her pain and 
autonomic dysfunction were alleviated within six days. A clear regress of muscle weakness 
began a few days later. Four months later her muscle strength was normal.  
 
5.3.2. Pain during an acute attack 
  
Abdominal pain was common and severe lasting usually for a few weeks (Table 16). All 
patients with acute PNP experienced abdominal pain. One third of the patients experienced 
pain in the back, which was less severe than abdominal pain.  
 
Table 16. Pain scoring during an acute attack 
Type of pain      16        % 
attacks       
VAS (0-10) 
Abdominal pain*† 14 88 9.4±0.9 
Pain in the back 5 31 7.8±1.7 
Pain in the extremities 11 67 9.1±1.1 
 Myalgia‡ 7 44 9.2±1.0 
 Dysesthetic 3 19 9.7±0.6 
 Arthralgia* 1 6 7 
Headache 4 25 8.0±1.4 
 Migraine-like 1 6 10 
 Non-migraine-like§ 3 19 7.3±0.6 
 
*First symptom during an acute attack. 
†In four cases laparotomy was performed.  
‡Including two patients with mild to moderate rhabdomyolysis 
§Associated with moderate hypertension in three cases. 
 
Headache was less common but severe when it appeared. In one case, it was the 
major symptom of pain, which appeared together with abdominal pain in the majority of her 
acute attacks and met the criteria for migraine (Nappi et al. 1989). Pain in the limbs was a 
common symptom manifesting as severe myalgia-type, deep and burning sensation which 
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lasted 1–2 weeks after the onset of muscle weakness (Figure 12). Opiates relieved pain and 
were used for 4 to 11 days. In four of our patients, laparotomy was performed to exclude 
abdominal crisis. 
 
5.3.3. Autonomic dysfunction 
 
Autonomic symptoms varied and developed before but occasionally simultaneously with 
muscle weakness or seizures (Table 17). Based on the 16 acute attacks analysed, constipation 
preceded abdominal pain. The tachycardia was the most common sign of autonomic 
neuropathy. It was often accompanied by systolic hypertension, constipation and abdominal 
pain. In case 4 supraventricular arrhythmia proceeded to a cardiac arrest. Vomiting lasted 1-2 
days and was accompanied by abdominal pain except one case. In case 8 autonomic 
symptoms such as hypotension and constipation were very mild. No intestinal dilatation 
could be found in four patients, who underwent diagnostic laparotomy.  
 
Table 17. Clinical manifestations caused by autonomic dysfunction during an acute attack  
 
Signs and symptoms       16           % 
  attacks        
Pain in abdomen  14 88 
Tachycardia  ≥100/min 15 94 
Arrhythmia  2 13 
 Supraventricular tachycardia or fibrillation 1 6 
 Ventricular tachycardia or fibrillation 0 0 
 Cardiac arrest 1 6 
Systolic hypertension  >145  mm Hg 12 75 
 >180 mm Hg 4 25 
Diastolic hypertension  >95 mm Hg 9 56 
Hypotension <80/<50 mm Hg 3 19 
Constipation  14 88 
Vomiting  6 38 
Pollacisuria   2 13 
Urinary retention  5 31 
Excessive sweating  1 6 
 
 
5.3.4. Peripheral neuropathy  
  
 Acute motor polyneuropathy was the most common neurological sign (Table 18). Muscle 
weakness accompanied by rapid atrophy was usually severe (Table 18) affecting both arms 
and legs. It was symmetrical at the onset of weakness except case 5, where asymmetrical 
weakness in the arms preceded severe symmetrical polyneuropathy. The presence of tendon 
reflexes varied: absent in eight attacks and reduced in four, but in three of them ankle jerks 
were preserved. Pattern of muscle weakness varied in each attack including intra-individual 
variation in patients with recurrent PNP, but usually proximal muscles in the legs were 
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affected more severely than distal. In the upper limbs no difference could be observed. 
Respiratory failure developed due to paresis of respiratory muscles, which required 
prolonged mechanical ventilation for 3 to 56 days. 
In  approximately 50% of acute attacks complain of numbness preceded sensory 
loss. One patient complained of numbness and pinprick sensation, but sensory deficits were 
not detected. Combination of PNP and focal CNS involvement was observed in half of the 
cases. 
 
Table 18. Manifestations and scaling of peripheral neuropathy during an acute attack  
 
Signs and symptoms  No of 
attacks 
% from attacks 
with PNP 
% from all 
acute attacks 
Motor polyneuropathy  
          Severe     (MRC-sum-score 0-25) 
          Moderate (MRC-sum-score 26-50) 
          Mild          (MRC-sum-score > 50) 
13 
10 
2 
1 
100 
78 
15 
             8 
81 
62 
13 
6 
Respiratory failure  10 78 62 
 Mechanical ventilation 8 62 50 
Cranial neuropathy 6 46 38 
 Bulbar palsy 4 31 25 
 Bilateral facial nerve pareses  4 31 25 
 Oculomotor nerve paresis 2 15 13 
Hypalgesia with glove-and-stocking distribution 6 46 38 
 + vibration sense loss 4 31 25 
Hypo/hyperalgesia with ”old-fashioned bathing 
costume ” distribution 
2 15 13 
Areas of paresthesia or dysesthesia and numbness 8 62 50 
Total number of attacks 16 13 16 
 
5.3.5. Rhabdomyolysis  
  
 5.3.5.1. Case report  
 
 A 36-year-old Estonian female (case 13) was admitted to the hospital because of severe 
abdominal, back and muscle pain, proximal muscle weakness, confusion and vomiting. 
Abdominal pain (VAS 10) and constipation developed 10 days before muscle weakness and 
confusion. She had used a combination of paracetamol and codeine and spasmolytic 
metamizole in a low dose for the abdominal pain. Previously she had had several 
premenstrual episodes of severe abdominal pain and constipation. Irritable bowel syndrome 
had been suggested. She had mild proximal muscle weakness, severe myalgia, lethargy, 
tachycardia and moderate hypertension.  Increased plasma creatinine kinase and myoglobin 
levels confirmed rhabdomyolysis. Decreased serum sodium together with 2:1 urinary/serum 
osmolarity ratio confirmed SIADH, which is one of the aetiological factors for 
rhabdomyolysis. The brain and whole body CT were normal. Thyroid-stimulating hormone, 
antinuclear and different viral antibodies including hepatitis B and C, human 
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immunodeficiency virus, influenza and Epstein-Barr virus, Chlamydia, Mycoplasma and 
Toxoplasma antibodies, toxins and drugs measured in the urine except opiates were negative. 
 
 
 Normal range 11.d 12.d 14.d 17.d 23.d 
S-Na 137-146 mmol/L 128 133 108 121 135 
U-Na 80-240 mmol/24 h   151 mmol/L  
S-osmolarity 285-300 mosm/kg H2O   222  279 
U-osmolarity   50-1200 mosm/kg H2O   459   
P-K 3.3-4.9 mmol/L 3.3 2.8 3.0 3.5 3.9 
S-Ca ionised 1.16-1.3 mmol/L   1.13  1.24 
P-CK <150 U/L   21806 1857 83 
S-myoglobin < 50 µg/L   2144   
Creatinine 40-90 µmol/L   37 39 56 
 
Figure 10. A course of an acute attack in a patient with rhabdomyolysis and SIADH 
 
   The patient was treated with hypertonic sodium chloride and sodium bicarbonate 
solution and water restriction. Her sodium and CK levels normalised within 10 days. Her 
muscle weakness and hypotrophy progressed slowly.  Tendon reflexes became low and 
proximal hyperalgesia could be detected. Slurred speech, bilateral positive Babinski signs, 
dysmetria in coordination tests and Romberg’s instability developed gradually within 10 
days. Abdominal pain and tachycardia persisted during that period. Hyporeflexia and 
proximal hyperalgesia could be explained by mild PNP, which manifested after 
rhabdomyolysis while an attack was proceeding. Treatment with haem-arginate for four 
consequent days together with opiates and beta-blockers alleviated her symptoms and she 
had rapidly recovered from autonomic neuropathy. Her muscle weakness and tone became 
completely normal in six months only. 
 
Premenstrum 
days
Abdominal pain 
Restlessness 
Constipation 
Weight loss 
Autonomic neuropathy   Rhabdomyolysis and PNP 
and mental disorder 
Muscle 
weakness  
 
Rhabdomyolysis    Hyporeflexia, hyperalgesia  
      Confusion         Dysarthria 
                               Babinski, dysmetria 
 Paracetamol, codeine, Metamizole (low doses)
Severity 
of the 
symptoms 
10 days                  11.                                      14.        17.            23.          35. day  
Admission to the 
hospital
Diagnosis of AIP 
Haem arginate 
Pulse, per min                 111       120             96   
Blood pressure, mmHg 176/105                138/85 
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5.3.6. CNS involvement 
 
Mild mental symptoms were common (Table 19) and present early at the beginning of an 
acute attack. When an acute attack proceeded extensor plantar was the most common sign of 
focal CNS involvement (Table 19). In two attacks, symmetrical muscle weakness caused by 
PNP proceeded to asymmetrical weakness with homolateral Babinski sign resembling 
hemiparesis. Sensory loss due to CNS impairment was suggested in three attacks (cases 1 
and 6). In case 1 during her first attack, focal spinal cord involvement could explain all 
symptoms additional to acute PNP (Table 22).  
 
Table 19. Clinical manifestations and scaling of CNS involvement during an acute attack 
  
16 attacks 13 attacks with 
PNP 
Signs and symptoms  
   N   %   N % 
Signs of corticospinal tracts involvement 7 44  6 46 
 Babinski signs 7 44  6 46 
 Hemiparesis 2 13  2 15 
Sensory loss due to CNS impairment 3 19  3 23 
 Hemianesthesia combined with hemiparesis 2 13  2 15 
 Paraanesthesia below Th4 level 1 6  1 8 
Mild cerebellar ataxia 2 13  2 15 
Nystagmus 2 13  1 8 
Epileptic seizures 5 31  3 23 
 Associated with hyponatraemia  
          129-134 mmol/L, soon after seizures 
 
3 
 
19 
  
2 
 
15 
Mental symptoms 14 88  11 85 
 Visual hallucinations 3 19  3 23 
 Anxiety 5 31  3 23 
 Depression 3 19  2 15 
 Mild dementia 2 13  2 15 
 Agitation 6 38  5 38 
 Euphoria  
Confusion 
2 
5 
13 
31 
 2 
3 
15 
23 
Anomic dysphasia 
Blurred vision 
1 
1 
6 
6 
 1 
1 
8 
8 
Level of consciousness       
 Normal 11 69  9 69 
 Lethargy 2 13  1 8 
 Stupor 0 0  0 0 
 Coma 3 19  3 23 
Signs of hypothalamus dysfunction      
 Fever (>37.2 o C) 9 56  7 54 
 Hyponatraemia <133 nmol/L 8 50  7 54 
 <120 mmol/L +hypokalaemia 4 25  4 31 
 
Seizures were either grand mal or secondarily generalised. In cases 8 and 14, 
recurrent seizures without or with mild hyponatraemia (Na 129-139 mmol/L) were a 
prominent sign of an acute attack, and together with fever, lethargy and Babinski signs led to 
misdiagnosis of acute encephalitis. In case 1, seizures were accompanied by hemiparesis 
with Babinski sign and low normal serum sodium (137 mmol/L) level suggesting other 
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possible mechanisms, not hyponatraemia for the seizures. In contrast, the case 13 with 
SIADH and sodium as low as 108 mmol/L experienced no seizures. The focal epileptiform 
discharges in the frontal area could be demonstrated during the serial generalised epileptic 
seizures in case 14. EEG was normal in remission in four cases with seizures during an acute 
attack. 
Mild ataxia together with bilateral Babinski sign manifested in two cases and vertigo 
due to hypertensive crisis in one case. One patient experienced short-lasting episode of 
blurred vision with normal fundoscopic examination before PNP manifested. 
Severe mental symptoms were present in one third of the attacks. They were short-
lasting and resolved completely within one month. Three of the most severely affected 
patients were in coma including two fatal cases, but only after the attacks had lasted more 
than a month. Autopsy of two patients revealed no focal brain abnormalities, but a diffuse 
loss of the cortical neurons similar to those reported previously.   
 
5.3.7. Precipitating factors and the course of an acute attack 
 
5.3.7.1. Precipitating factors 
 
Precipitating factors, responsible for an early phase of an acute attack or provoking more 
severe neurological symptoms later, varied and appeared usually in combination (Figure 11). 
The initial provocation, either endogenous (n=9 attacks) or exogenous (n=2 attacks) and in 
some cases combined (n=5 attacks), was followed by exogenous provocation such as drugs. 
Weight loss due to inappropriate nutrition was responsible for proceeding  an acute attack in 
two cases. 
 
5.3.7.2. Clinical course of an acute attack 
 
Signs of autonomic dysfunction and mental symptoms were prominent in the early phase of 
an acute attack lasting for 3 to 29 days (mean 11 days). Paresis or seizures were never the 
first sign of an acute attack but appeared after administration of an additional precipitating 
factor. If precipitating factors were removed pareses developed fully within 30 days (mean 
13.3 days, range 3-27 days) even without a specific treatment and remained in a plateau 
phase for less than a month before recovering. If paresis proceeded, an additional 
precipitating factor could be identified.  Mechanical lung ventilation, bulbar paresis, severe 
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consciousness impairment and arrhythmia developed only at the late stage of an acute attack 
(mean 45 days, range 13-83 days).  
 
Figure 11. Staging of  an acute attack and connection with precipitating factors in 16 
attacks.+  indicates combination of factors/drugs  in individual patients 
 
The abdominal pain intensity usually declined by the time paresis developed, however, pain 
in the muscles manifested together with progressing muscle weakness (Figure 12). 
 
 
 
Figure 12. Onset and duration of symptoms in 14 acute attacks.  
Abdominal pain (dotted line), pain in the back (dash line), pain in extremities (thick solid 
line), muscle weakness (thin solid line). 
 
5.3.7.3. Hepatopathy 
 
In a retrospective evaluation of 99 acute attacks with and without neurological 
manifestations in 12 Russian and 35 Finnish patients, alanine aminotransferase (ALT) was 
elevated in 49 (50%) of acute attacks especially if it was prolonged. In case 1 with severe 
PNP, the highest level of ALT (269 U/L) was observed. ALT was normal until the 2nd -27th 
clinical 
severity 
 of the 
symptoms 
duration of 
 an attack 
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days of an acute attack (mean 9.7 days). Maximal elevation of ALT was observed on the 4th 
to 60th day of an acute attack (Mean 27.4 days). It was normal if an acute attack lasted less 
than six days (except of a few cases with chronic hepatitis). Fluctuations of ALT followed 
the clinical course and ALT-peaks followed a clinical nadir with a few days delay. ALT rise 
could continue even after the clinical plateau phase. ALT returned to the normal range within 
1-1.5 months depending on the previous elevation range. 
Case 13 with rhabdomyolysis had the highest aspartate aminotransferase (AST) level 
(601 U/L). The peak of AST was observed on the same day with the clinical manifestation of 
rhabdomyolysis (Figure 10). The peak co-segregated with normal GTP (25 U/L) and 
elevated ALT (128 U/L) suggesting muscular origin of AST elevation. Eight days later, 
when rhabdomyolysis subsided but an acute attack proceeded, the values of AST decreased 
(116 U/L), at the same time the peak of ALT was observed (233 U/L). 
 
5.4. TREATMENT 
 
Acute attacks were treated with 20% glucose-infusions (300-500 g/day, 5-12 days, n=7) 
(Tschudy et al. 1964) or haem arginate (Normosang ®, 2.5-3 mg/kg, 4 days, Orphan Europe, 
France, n=7) (Mustajoki, Nordmann 1993) after the diagnosis of AIP was confirmed. The 
choice of treatment was based on availability of haem arginate solely.  
 
Table 20. The results of the treatment 
 
Patient 
 
   Treatment 
The day of initiation of 
treatment from the onset 
of an acute attack 
The day of initiation 
of recovery from the 
start of treatment* 
Complete recovery 
I. Haem arginate   
1, 2nd attack 21. +7 Mild residual paresis 
3 48. +10 Deceased 
5 26. +3 4 mo 
6 19. +7 12 mo 
10 52. +8 11 mo 
13 23. +9 6 mo 
14 12. +5 1 mo 
Mean±SD 28.7 ±15.2 +7.0±2.4   6.8±4.6 mo 
II. Glucose‡    
2 13 +9 7 mo 
4 42. +15 Deceased 
7 25. +12 6 mo 
8 8. +7 1 mo 
9 9. +10 7 mo 
11, 1st attack 7. +13 Mild residual paresis 
11, 2nd attack 4. +14 Mild residual paresis 
12 6. +7 1 mo 
Mean±SD 14.3 ±13.0 +10.8±3.1 4.4±3.1 
p 0.04 0.035 0.52 
*The criteria included decline of the pain VAS<3, blood pressure <140/95 mm Hg, normal 
consciousness, absence of new symptoms. ‡Only >300g/day considered as the treatment 
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Although the treatment with haem arginate was started late, the plateau phase was 
detected significantly earlier in the patients treated with haem than those treated 
conventionally (Table 20). Minimal improvement of muscle weakness could be recorded a 
week after the last infusion. In cases 3 and 6, progression of neurological deficit required 
four more infusions of haem arginate resulting in a second plateau phase in case 6, but not in 
case 3, who experienced septicemia leading to a fatal outcome.  
Of the eight patients experiencing acute attacks during the follow-up period (range 4-
9 years), five cases (1, 5, 8, 12 and 13) were treated with haem arginate for 1-4 days after the 
onset of an acute attack and no neurological deficits was observed. In contrast, case 11, who 
was one of the three cases (7, 9 and 11) with recurrent attacks and treated conventionally 
with 20% glucose 2-4 days after the onset of acute attack, had her earlier distal pareses 
worsened as a sign of acute motor polyneuropathy (Table 20). 
In 14 attacks opiates were used for a week or longer with no serious side effects or 
risk of abuse. Beta-blockers were used in all cases to correct tachycardia and mild or 
moderate hypertension. In two cases of hypertensive crisis (blood pressure > 220/120 mm 
Hg), the drugs were inefficient and other medications such as clonidine, pentamine and 
calcium blockers were used. No additional anticonvulsants except diazepam for a few days 
were administered to the patients with seizures after hypertension and hyponatraemia were 
corrected.   
 
5.5. SURVIVAL AND RECOVERY FROM AN ACUTE ATTACK  
(Article I and additional data) 
 
When duration of an acute attack before the diagnosis of AIP was compared to the long-term 
prognosis of the patients, a clear difference was observed between the patients who survived 
(18.3±12.1 days, n=12) and the patients who died of an acute attack (44.0±4.2 days, n=2). 
This suggestes that misdiagnosis and malpractice were the main causes for a poor prognosis.  
If the patients who recovered within six months (20.6±14.2 days, n=5) were compared to 
those who needed a longer period of more than 6 months to recover completely (15.2±19.2 
days, n=7), no such correlation could be demonstrated suggesting that additional endogenous 
mechanisms can be involved in maintaining the neurological deficits.  
The pneumonia following mechanical ventilation and accompanied by septicaemia 
and coagulopathy was the cause of death in one patient. Recurrent episodes of ventricular 
fibrillation resulted in a cardiac arrest in the second case. The full recovery from muscle 
weakness was observed in one year in all but two patients who experienced mild residual 
distal pareses (Table 20). 
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5.6. SCORING OF SYMPTOMS 
   (Article I) 
 
Twelve Russian patients were grouped according to the short- and long- term outcome: 1) a 
complete recovery within ≤6 months. 2) a complete recovery within >6 months or with 
residual signs (pareses) and 3) a death during an acute attack (Article I, Table 1).  
Fifteen covariates were initially evaluated for scoring the symptoms and scored (0-10) 
according to their clinical importance (Article I, Table 1).  0-60 MRC-sum score (Kleyweg et 
al. 1991) was transformed to a motor score ranging from 0 to 6. Of these, a significant step-
wise increase between prognostic groups I-III could be identified in five of them (X1-X5: 
muscle weakness, mechanical ventilation, bulbar palsy, unconsciousness and hyponatraemia) 
and a non-significant step-wise increase for arrhythmia and seizures. The symptoms and 
signs which showed no significant step-wise increase between three prognostic groups were 
excluded from the further calculations and scored 0. For the covariates X1-X5 (Article I, 
Table 1) the coefficients α had approximately the same values (range 0.39-0.51) and thus, 
they were assigned similar points in our scoring system. Each of them was graded from 0 to 
6 comparable to the 0-6 scale initially chosen for the muscle strength.  
 
Table 21. The long-term follow-up and scores of the 12 Russian patients during an acute attack 
  
  Complete 
recovery ≤6 
months 
Complete 
recovery > 6 
months or 
residual signs* 
Deceased 
during an acute 
attack 
Patients   n=4 n=6 n=2 
Group (scores)  I  (<5)  II  (5-25) III  (>25) 
 Scale Total 
mean 
scores†
Mean Range  Mean Range Mean Range
Scores from MRC  (60-MRC/10) 0-6 3.6 1.25 0-3  4.8 4-6 5.5 5-6 
  MRC score sum 0-60 25.5 48.5     34-60 14.5     0-24 6 0-12 
Scores from mechanical ventilation  0-6 2.1 0   2.6       0-6 6 6 
 Duration of mechanical 
ventilation. d 
0-56 21.3 0   10.2     0-31 44 32-56 
Bulbar palsy  0-6 2.1 0   2 0-6  6 6 
Impairment of consciousness  0-6 1.4 0.25 0-2  0.5 0-6  6 6 
Hyponatraemia 0-6 1.9 0 0  2.5 0-6 6 6 
Total scores ‡ 30 11.1 1.5  0-3  12.4 6-24 29.5 29-30 
Duration of an acute attack before 
diagnosis of AIP was confirmed, d  
  20 6-25  16 9-51 44 41-47 
 
*Mild not progressing weakness in wrist and feet in cases 1 and 11. 
†Total mean scores are evaluated from 12 attacks with neurological symptoms, in subgroups from 
the most severe attack in each patient. 
‡ANOVA, p=0.0006.  
 
The total score (maximum 30) for each patient is a sum of scores including muscle 
strength (0-6), ventilation time (0-6), bulbar palsy (0/6), impaired consciousness (0-6) and 
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hyponatraemia (0-6). The total mean scores were calculated for each patient groups and 
compared to the clinical outcome of the patients within the group (Table 21) during the 
follow-up period of 24 months. A significant difference among the groups I-III was 
demonstrated (p=0.0006. Table 21) and the scale of an acute attack could be established 
(Article I, Table 2).  
The classification of acute attacks by their severity was established (Article I): mild 0 
scores; moderate 1-4 scores; severe 5-25 scores; critical >25 scores.  According to this 
classification one Finnish patient (case 13) had a severe acute attack (severe hyponatraemia, 
muscle weakness, lethargy, 9 scores) and another Finnish patient (case 14) had a moderate 
acute attack (mild hyponatraemia, 3 scores), which corresponded to a complete recovery 
within 6 and 1 month, respectively. 
 
 5.7. NEUROPHYSIOLOGICAL STUDIES  
(Article II) 
 
Features suggestive of demyelination in at least one motor nerve could be demonstrated in 
five of the six patients with PNP studied during an acute attack (Article II, Figure 1).  In four 
cases more than two nerves were affected. In 80% of the nerves studied, MCVs were 
decreased ranging from 15 to 50 m/s (32% to 97% of LNL). Slowing of MCV within the 
range of demyelination could be demonstrated in four patients.  
Decreased MCV with normal DL was not rare. However, DL was prolonged in at 
least two nerves in all patients, which was more commonly observed in the lower extremities 
than in the upper extremities. In one case dramatic prolongation of DL reaching the level of 
demyelination (9.2-9.8 s) was observed. Prolongation of DL was always associated with the 
decrease in MCV of the same nerve.  
F-waves could not be evoked in three patients (Article II, Figure 1) who had the 
lowest MCVs. In other patients FL was prolonged in all nerves studied, and it was always 
within the range of demyelination in the median nerve (44.3-56.4 s). In one patient it was the 
only demyelinating sign, and thus, did not fulfill the criteria of demyelinating PNP.  
All six patients had also signs of axonopathy: CMAP amplitudes were <50% of LNL 
in 86% of the nerves studied (range 0.1-10.4 mV). Of note, CMAP amplitude <10%LNL or 
undetectable CMAPs indicating severe axonal loss could be demonstrated in one to four 
nerves only in three patients. Two of three nerves, where CMAP could not be evoked, were 
radial. The amplitudes of  CMAP in eight additional  nerves (20%) were within 10 to 30% of 
LNL. 
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In summary, a mixed pattern of PNP was identified in four patients. They had usually 
more severe muscle weakness: in three patients the MRC sum of score was 0-4, and it was 
40 in one patient with a few demyelinating features..  
A demonstrative case 3 is a 36-year-old previously healthy pregnant woman with 
severe acute neuropathy. During her first and fatal attack, MCV as low as 15-27 m/s in seven 
nerves was detected on the 8th day from the clinical onset of PNP (Article II, Figure 1) 
suggesting that demyelination is an early phenomenon in acute porphyria. Two patients 
classified with pure “axonal“ PNP had moderate muscle weakness (MRC sum of score 24-
34). 
Sensory conduction velocities (SCV) were decreased in all nerves studied (range 17-
48 m/s) including a patient without sensory loss, which suggests that sensory neuropathy 
may be subclinical in AIP. SCV was <70% LNL (17-25 m/s) in two patients probably 
indicating demyelination. 
Needle EMG revealed signs of denervation such as fibrillation potential and positive 
sharp waves both in the proximal and distal muscles. Signs of reinnervation such as 
prolonged large amplitude polyphasic motor unit potentials were detected in five patients. 
Two of them were examined within two weeks from the onset of muscle weakness 
suggesting that those findings could result from previous, although asymptomatic, episodes 
of denervation. One patient with respiratory failure had positive waves and prolonged MUPs 
in diaphragm muscle, prolonged DL (11.3 ms) and decreased CMAP amplitude (0.12 mV) in 
phrenic nerve suggesting neurogenic origin of respiratory failure.  
Most of the electrophysiological abnormalities improved in remission with an 
exception of one patient with mild monthly attacks. MCV and SCV values decreased in 50% 
of the nerves studied suggesting new episodes of subclinical PNP. Two patients, who 
experienced residual distal paresis, showed similar MCV and DL in the median nerve as the 
others, but CMAP amplitudes were more decreased when compared to the patients without 
neurological deficits in remission (0.1-0.3 mV vs. 3.2-8.5 mV). This suggested that axonal 
loss was responsible for residual pareses. Levels of porphyrin precursors in urine did not 
correlate with the residual neurophysiological abnormalities. 
Subclinical sensorimotor PNP was confirmed in two patients with no clinically 
evident PNP during an acute attack since at least seven abnormal findings (MCV and/or FL, 
and SCV) could be detected in both patients. In contrast, the amplitudes of motor and 
sensory evoked potentials were normal. Since the abnormalities were mild (±20% of the 
reference values) and fulfilled neither the criteria for demyelination nor axonopathy, it was 
classified as unspecific PNP (Hadden et al. 1998).  
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5.8. NEUROIMAGING 
 
In seven cases brain CT or MRI was performed during clinical manifestations of focal CNS 
involvement. In two cases, focal lesions could be identified during an acute attack (Figure 
13, Table 22) when they were performed within 24 h of the nadir of encephalopathy. In case 
13, a reduced bright signal at was T1 detected in the posterior pituitary ten days after severe 
hyponatraemia due to SIADH (Figure 14). This finding favours inappropriate release rather 
than inappropriate secretion of ADH, which might be a sign of transient pituitary 
dysfunction.  
  
 
Figure 13. PRES in a case 14.  T2 weighted MR imaging (TR 3528 ms/TE 90 ms) reveals 
wide areas of increased signal intensity (A). In axial fluid-attenuated-inversion-recovery 
(FLAIR, TR 9999 ms/TE 105 ms) image sequences mild hyperintensity is found in left 
occipital lobe (B, arrowhead). Diffusion weighted MRI imaging (TR 0 ms/TE:137 ms) 
reveals an increased diffusion coefficient in the parasagittal cortex within occipital lobes as 
a sign of focal oedema. A combination with decreased ADC values within the same area 
suggesting secondary cytotoxic edema (C, arrowhead).  
 
 
Figure 14. Case 13 MRI (T1): reduced bright signal from posterior pituitary  
(A, arrowhead). The normal posterior hypophysis can be demonstrated as a bright spot 
within the sella turcica on T1-weighted MRI (B, arrowhead). 
 
(A) (B) (C)
(A) (B)
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Table 22. Clinical manifestations and neuroimaging data of nine patients during an acute attack and 
in remission 
 
Case Clinical manifestations*  Neuroimaging 
1 1st attack Acute neuropathy, paraanesthesia 
below Th4, urinary retention, 
Babinski signs 
Not performed 
1  2nd attack Acute PNP, hemiparesis, Babinski 
sign, mental symptoms, secondarily 
generalised seizures (last episode 
16 h before CT), hypertension 
180/100 mm Hg during seizures,  
Na 137-140 mmol/L  
CT (no contrast enhancement):  
two symmetrical reversible hypodensive foci 
(20 and 21 HU) in subcortical white matter of 
fronto-temporal lobes, 13 and 22 mm 
1 1.5 mo 
later 
Residual signs of PNP MRI (T1, T2): normal  
3 attack Acute PNP, lethargy,  mental 
symptoms during MRI, blurred 
vision 10 days before MRI 
MRI (T1, T2): normal  
5 1st attack Hallucinations, depression MRI (T1, T2): normal 
5 2nd attack Acute PNP, mental symptoms Not performed 
6 attack Acute PNP, Babinski sign, 
hemiparesis, hemianesthesia 
Not performed  
6 4 mo 
later 
Muscle weakness, Babinski sign, 
hemianesthesia  
MRI (T1, T2): normal 
8 attack Lethargy, seizures, Babinski signs 3 
days before MRI 
MRI (T1, T2): normal  
10 attack Acute PNP, Babinski signs, mild 
cerebellar ataxia, nystagmus  
Not performed  
10  1.5 mo 
later 
Muscle weakness, Babinski signs  MRI (T1, T2): liquor cysts 3 and 4 mm in left 
cerebellar hemisphere, and left temporal 
lobe, small paraventricular liquor density foci 
10 2 y later Symptom-free  MRI (T1, T2): no regression 
12 attack Vertigo, nausea, nystagmus, mental 
symptoms 10 days before MRI 
MRI (T1, T2): normal 
13 attack Severe SIADH (Na 108 mmol/L), 
rhabdomyolysis, confusion, MRI 
after correction of hyponatraemia   
MRI (T1, T2): Decreased bright spot signal 
from neurohypophysis at T1 
CT (+contrast enhancement):small unspecific 
hyperdensive area in the left frontal cortex 
14 attack Seizures, confusion, Na 129 mmol/L 
during MRI 
MRI (T1, T2, FLAIR, DW):  
↑T2 signal: wide occipital, frontoparietal and 
temporal cortical areas  
↓T2: signal: small area (5 mm) in left 
cerebellum 
↑DW/↓ADC: left occipital and parasagittal 
area (2 mm) 
PC MRA: normal 
14 10 days 
later 
Symptom-free MRI (T1, T2, FLAIR, DW): 
↑T2 areas diminished 
↓T2: signal in left cerebellum disappeared 
14 1.5 mo  Symptom-free MRI (T1, T2, FLAIR, DW): normal 
 
* Severe abdominal pain in all cases except 8 and 12..  
FLAIR, fluid-attenuated-inversion-recovery imaging;. DW, diffusion weighted imaging; PC MRA, 
phase contrast magnetic resonance angiography 
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5.9. IDENTIFICATION AND CHARACTERISATION OF THE MUTATIONS IN 
THE HMBS GENE 
(Article III and additional data) 
 
5.9.1. Mutations identified among patients with AIP 
 
Mutations in the HMBS gene were revelead in all AIP patients studied by DNA analysis. Of 
the 13 families with AIP studied, 11 mutations could be identified in the HMBS gene (Tables 
23 and 24). The mutations were family-specific and only two mutations, (p.R26H and 
p.R173W) could be identified in two unrelated families. 
Of the 33 family members studied by mutation analysis, ten additional patients with 
AIP could be identified (Table 23, Figure 8). Only two of the latter group had increased 
urinary porphyrin precursors.    
 
Table 23. Mutations identified in families with AIP and biochemical characteristics of the symptom-
free AIP patients 
 
Urine samples in 
remission 
Family 
(=case) 
No/ 
members/ 
AIP patients 
Origin Mutation Pt* Age† 
y/ 
Sex ALA 
(<34 
μmol/L) 
PBG 
(<9 
μmol/L) 
Erc-HMBS activity 
in remission 
(55-100 
uroporphyrin/mg 
prot) 
1/3/2 Russian c.77G>A 1 7/F 13 5 25 
2/3/2 Russian c.770T>C 1 18/F 1 6 37 
3/3/3 Russian c.825+5G>C 1 
2 
17/F 
20/M 
42 
17 
11 
4 
39 
40 
4/1/1 Kazakhian       
5/5/1 Russian/ 
Polish 
c.517С>Т      
6/1/1 German c.748G>С      
7/5/1 Russian c.77G>A      
8/3/2 Russian/ 
Chuvashian 
c.673C>T 1 51/M No sample available 
9/3/1 Russian c.739Т>С      
10/6/2 Russian c.825+3_825+6del 1 54/F 53 47 68 
11/8/2 Russian c.517С>Т 1 5/F Not informative in 
childhood 
41 
12/4/3 Russian c.583C>T 1 
2‡ 
56/F 
30/F 
24 
3 
5 
3 
43 
44 
13/2/2 Estonian c.1000_1018del 1 9/F Not informative in 
childhood 
31 
14/1/1 Indian c.652-2del      
 
*Asymptomatic patients with AIP identified by a mutation analysis among the family members. †By 
the time of examination. ‡Chronic renal insufficiency and haemodialysis after an acute attack. 
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Of the three RT-PCR fragments (611 bp ∼60%. 492 bp ∼30% and 453 bp ∼10%). which  
 
 
 
 
 
 
 
 
 
 
Figure 15. Identification of novel mutations using manual (A-B) and automated (C) direct 
sequencing of HMBS gene in the presence of mutation-negative control. The mutations 
770T>C and c.825+5G>C are seen as an extra band in PAGE electrophoresis (A-B) or as a 
double wave in automated sequencing (C) for a heterozygous patients. Mutations 
c.825+3_6del (B) and1000_1018del (C) are seen as a double sequencing from the point of 
deletion.  
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Table 24. Mutations identified in patients with AIP 
 
In vitro expression  
    Mutation 
 
Restric-
tion 
enzyme 
 
mRNA  
 
cDNA*
 
Outcome Erc-HMBS 
activity† 
(nmol/mg 
prot/h) 
Mean (range)
% 
Ex 3 c.77G>A1 AciI r.77g>a +1 p.R26H  3.9‡ 
Ex 10 c.517С>Т2 MspI r.517c>u +2 p.R173W 59 (31-86) 1 (1§) 
Ex 10 c.583C>T3 HhaI r.583c>u n.d. p.R195C  34 (23-49) 0.2. 
Int 11 c.652-2del - [r.652_771del, 
r.613_771del 
+ p.G218_L257del 
p.I205_L257del 
40 (32-49) 
30 (30-30) 
0.3 
0.1 
Ex 12 c.673C>T3 Cac8I r.673c>u -3 p.R225X 57 (36-78) 0.9 (0§)
Ex 12 c.739Т>С4 AciI r.739u>c +4 p.С247R 27 (17-37) 0.1 
Ex 12 c.748G>С5 - r.748g>c n.d. p.Е250А 35 (23-48) 0.3 
Ex 12 c.770T>C MspI [r.770u>c, 
r.652_771del, 
r.613_771del] 
+ 
+ 
+ 
[p.L257P, 
p.G218_L257del, 
p.I205_L257del] 
38 (34-43) 
40 (32-49) 
30 (30-30) 
0.2 
0.3 
0.1 
Int 13 c.825+5G>C BsrI r.822_825del + p.C275fsX2 29 (16-46) 0.1 
Int 13 c.825+3_6del - r.spl? - p.?   
Ex 15 1000_1018del  BalI r.1000_1018del - N333fsX3 84 (50-249) 1.3 
 2519  
(861-4786) 
100 SVpoly-HMBS-wild type 
 
SVpoly expressed in COS-1 cells  26 (18-43) 0 
 
Novel mutations are indicated in bold. 
1(Llewellyn et al.. 1993); 2(Lee. Anvert. 1991); 3(Kauppinen et al.. 1995); 4(Mgone et al.. 1993); 
5(Lundin et al.. 1995). 
* + mutation identified in cDNA sample; - no mutation identified in cDNA. n.d. not done. 
†in four independent transfections. ‡(Ong et al.. 1997) in E.coli; §(Mustajoki et al.. 2000) in COS-1 
 
5.9.2 Novel mutations identified in the HMBS gene 
 
In Family 2 a patient and her daughter were heterozygous for the point mutation c.770T>C, 
which is the second last nucleotide in the exon 12 (Table 24, Figure 15). In Family 3 direct 
sequencing of genomic DNA samples from two symptom-free children of a patient who died 
during an acute attack demonstrated a point mutation, c.825+5G>C, in the boundary region 
of exon and intron 13 (Figure 15).  
In Family10 direct sequencing of genomic DNA samples of a patient and her 
symptom-free sister demonstrated a deletion of 4 bp in the position 3-6 of intron 13, 
c.825+3_825+6del,  suggesting an alteration of the splice site (Figure 15). The mutations 
c.770T>C, c.825+5G>C and c.825+3_825+6del co-segregated with the low erythrocyte 
HMBS activity in these family (Tables 13 and 23). 
A novel mutation 1000_1018del (N333fsX3) was identified in Family 13 (Figure 15). 
Repeated studied of Erc-HMBS activity showed normal results in her case (77-81, normal 
55-100 uroporphyrin/mg prot) despite the absence of any obvious iron deficiency or 
enhanced erythropoesis. However, decreased Erc-HMBS activity (31 uroporphyrin/mg prot) 
detected in her son indicated that this mutation caused a non-variant form of AIP. 
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5.9.3. The effects of the novel mutations 
 
In two of four novel mutations c.825+5G>C and c.770T>C abnormal cDNA sequences could 
be identified (Table 24). Sequencing of cDNA from c.825+5G>C mutation revealed 
del822_825 transcript (Figure 16). The mutation c.770G>C resulted in missense mutation 
r.770u>c (p.L257P) or deletion of exon 12 (r.652_771del. p.G218_L257del) or deletion of 
exons 11 and 12 (r.613_771del. p.I205_L257del).  
 
Figure 16. Identification of abnormal cDNA (r.822_825del) resulted from the mutation 
c.825+5G>C by direct sequencing of E.coli clone containing the mutation 
 
No abnormal cDNA could be revealed in patients with mutation c.825+3_6del and 
1000_1018del (suggested polypeptide N333fsX3). Both patients with mutation c.825+3_6del 
were heterozygous for the intraexonic SNP in exon 10: c.606 G>T which confirmed that 
even after subcloning of RT-PCR-products no abnormal allele with a 606T polymorphism 
could be demonstrated. This suggests too low stability of abnormal mRNA species to be 
identified using RT-PCR technique or too low transcription rate of mutant transcript (<30%) 
(Kauppinen et al. 1995; Mustajoki et al. 1997). 
In expression studies, the residual enzyme activities of all ten abnormal transcripts 
expressed in COS-1 cells were reduced close to the background level (Table 24) confirming 
the loss of function of the mutants. 
 
5.10. THE GENOTYPE-PHENOTYPE CORRELATION 
(Article IV) 
 
To investigate a genotype-phenotype correlation of different mutations, Finnish and Russian 
AIP families sharing a mutation were pooled, with the material limited to those mutations 
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where data was available from at least 6 patients for each mutation. Thus, 10 different 
mutations and 23 AIP families including 190 patients were selected. The patients who were 
younger than 15 years at the time of the study or died before 1966 or patients whose clinical 
data were not available were excluded. The study population consisted of 143 heterozygous 
AIP patients with ten common mutations (c.33G>T, c.97delA, InsAlu333, p.R149X, 
p.R167W, p.R173W, p.R173Q, p.R225G, p.R225X, c.1073delA) (Figure 17). Eighty eight 
patients were asymptomatic individuals who had never experienced an acute attack requiring 
hospitalization and 55 patients had experienced one or several attacks (Article IV, Figure 2).  
 
23 Russian AIP patients  287 Finnish AIP patients 
12 symptomatic (1995-2003)  116 symptomatic (1966-2003) 
11 asymptomatic  171 asymptomatic 
12 families  45 families 
9 mutations in the HMBS gene  26 mutations in the HMBS gene 
   
 
 
 
143 patients 
≥6 patients in each mutation group 
23 families 
10 selected mutations 
 
Figure 17.  Study group for an analysis of a genotype-phenotype correlation  
 
5.10.1. Correlation between the genotype and clinical symptoms 
 
Patients with the p.R167W and p.R225G mutations showed lower penetrance (19% and 
11%) than patients with other mutations (range 36 to 67%, Article IV, Table 1). Recurrent 
attacks were rare for patients with the p.R167W and p.R225G mutations occurring in only 
two of six symptomatic patients, none of whom experienced paresis. In contrast, 17 (50%) of 
34 patients with the p.R149X, p.R173W,p.R173Q, and p.R225X mutations experienced 
subsequent attacks after diagnosis of AIP resulting in severe neurological symptoms and 
paresis in six of them (36%). The high percentage of subjects diagnosed late in their life 
spans with mutations p.R167W or p.R225G (9 patients) suggested that these patients were 
more likely to be symptom-free and to live longer. Median age at the onset of symptoms was 
23 years but was remarkably higher, 45 years (range 40 to 46 years), among patients with the 
p.R167W mutation. 
The patients with variant form of AIP (c.33G>T) were chosen as a reference group 
and a multivariate logistic regression analysis was performed, adjusted for the age, gender, 
and the year of the diagnosis (Article IV, Table 2). The analysis revealed that the risk for 
acute attacks was highest for patients with the c.97delA, p.R149X and p.R173Q mutations, 
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whereas the risk of attacks was lowest for patients with the p.R167W and p.R225G 
mutations. No significant differences existed between the other mutation groups. In a model 
including only mutation type as an explanatory variable, Cox & Snell R2 and Nagelkerke 
R2, which are estimates of the R2 statistics in linear regression summarising how much of 
the variability in the data could be explained by the model, were 0.135 and 0.183, 
respectively (the maximum value for Cox & Snell R2 is less than one, for Nagelkerke R2 is 
one). That indicates that the genotype determines less than 20% of the variation in clinical 
penetrance. 
The cases with hepatoma were distributed evenly among the different mutation 
groups (Article IV, Table 1) including milder mutations p.R167W and p.R225G. 
 
5.10.2. Correlation between the genotype and biochemical characteristics 
 
The patients with the mutations p.R167W and p.R225G showed significantly lower urinary 
PBG excretion in remission than the others (PBG pooled: 47±10 vs. 163±21 μmol/L, 
p<0.001, Article IV, Table 4, Figure 3). Similarly, urinary ALA, uroporphyrin and 
coproporphyrin excretions were significantly lower in the patients with these two mutations 
than in the others (ALA pooled: 40±6 vs. 104±11 μmol/L, p<0.001, uroporphyrin pooled: 
130±40 vs. 942±183 nmol/L, p<0.001, coproporphyrin pooled: 399±77 vs. 610±54 nmol/d, 
p=0.01).  
 
5.10.3. Correlation between urinary PBG excretion and clinical symptoms 
 
In order to study the correlation between the urinary excretions, erythrocyte HMBS activity 
and occurrence of clinical symptoms the patients were divided into two groups: group A with 
low PBG excretion including the patients with the mutations p.R167W and p.R225G and 
group B with high PBG excretion including the patients with the mutations c.33G>T, 
c.97delA, InsAlu333, p.R149X, p.R173W, p.R173Q, p.R225X and c.1073delA (Article IV, 
Figure 3). Low PBG excretion correlated with a less severe disease, since only six out of 36 
patients (17%) experienced acute attacks in the group A (Article IV, Table 1), whereas 49 
(46%) of 107 patients were symptomatic (p=0.003) in the group B. Furthermore, subsequent 
attacks were less frequent in the group A occurring only in two of six symptomatic patients 
(33%) and none of them experienced paresis. In contrast, 22 (45%) of 49 symptomatic 
patients experienced subsequent attacks in the group B resulting in paresis in eight patients 
(36%). The patients with the c.97delA mutation had the highest clinical penetrance (67%) 
accompanied by a three-fold level of excretion of urinary PBG. Regardless of the mutation 
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type, all patients with normal urinary PBG excretion (<9 μmol/l, n=13) were symptom-free 
(Article IV, Table 5). 
 
5.10.4. No correlation between erythrocyte HMBS activity, urinary PBG excretion and 
clinical symptoms 
 
A significant positive correlation existed pairwise between all urinary and some faecal tests, 
mainly for faecal coproporphyrin, but not between any of these tests and erythrocyte HMBS 
activity. The correlation coefficients varied from 0.60 to 0.83 (p<0.0001) for all urinary tests 
and from 0.06 to 0.85 (p=0.0001-0.7) for faecal tests. 
 When the patients with the c.33G>T mutation causing the normal erythrocyte HMBS 
activity were excluded from the comparison the mean erythrocyte HMBS activities for 
groups A (n=29) and B (n=49) were 39±2 and 36±1 nmol/mg prot/h, respectively (p=0.3).  
Among the patients with the classical form of AIP, 19 (36%) of 53 patients with the 
erythrocyte HMBS activity < 40 nmol/mg prot/h experienced acute symptoms, whereas 11 
(44%) of 25 patients with the erythrocyte HMBS activity ≥ 40 nmol/mg prot/h were 
symptomatic. This indicates that the high expression level of the normal allele in 
erythrocytes alone could not predict freedom from the clinical manifestations.  
We have compared the clinical manifestations between the group including the 
mutations c.97delA and p.R173Q with the lowest erythrocyte HMBS activities and another 
group including the other mutations. In the former group 15 of 34 patients (44%) 
experienced acute attacks, whereas in the latter group 40 of 109 patients (37%) were 
symptomatic. This indicates that in the patients with the classical form of AIP, the 
erythrocyte HMBS activity does not correlate with the PBG excretion in remission or with 
the severity of the disease.  
Acute attacks were less frequent among the patients with the variant form of AIP and 
the c.33G>T mutation occurring in only 2 of 12 (17%) patients, whereas 53 of 131 (40%) 
patients with the classical form of AIP were symptomatic. 
 
Table 25. Comparisons of the patient’ groups based on cross-reacting immunological material class 
 
 CRIM + 
p.R149X, p.R167W, 
p.R173W, 
p.R173Q,  
CRIM – 
c.33G>T, c.97delA, 
InsAlu333, p.R225G, 
p.R225X, c.1073delA 
CRIM- with residual 
HMBS activity in vitro  
p.R225G, c.1073delA 
U-PBG, µmol/L 127±22* 106±20 52±21 
Erc-HMBS, nmol/mg prot/h 39±2 37±1† 35±2 
Penetrance, % 39 38 27 
 
*Mean ± SEM. †Variant form (c.33G>T) is excluded 
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Cross-reacting immunological material (CRIM) positive mutations detectable by 
HMBS-specific antibodies (Anderson et al. 1981) were pooled and compared with CRIM 
negative mutations but no significant differences in porphyrin excretions or enzyme 
activities could be observed (Table 25).  
The mutations p.R225G and c.1073delA that maintain 16% and 50% residual HMBS 
activity in vitro (Mustajoki et al. 2000) showed significantly lower PBG (52±21 vs.166±16 
µmol/L, p< 0.009) and ALA (33±7 vs. 106±11 µmol/L, p< 0.017) excretions than other 
CRIM- mutations, but in Erc-HMBS activities no significant differences existed (Table 25 
and Article IV, Figure 4). 
 
Table 26. Clinical and biochemical findings in patients with milder phenotype for p.R167W and 
p.R225G mutations vs. AIP patients with other eight selected mutations  
 
Comparison with 
another mutations 
Clinical findings Biochemical 
findings 
Lower, compare 
with another 
mutations 
Penetrance (occurrence of acute attacks)  
Recurrence of acute attacks after diagnosis of AIP 
Severity of recurrent attacks (neurological 
manifestations during recurrent acute attacks) 
Mortality due to acute attacks 
Urinary ALA 
Urinary PBG 
Urinary 
uroporphyrin 
No difference Mortality due to hepatoma Erc-HMBS 
 
5.11. PROGNOSIS OF AIP PATIENTS  
(Article IV) 
 
According to the analysis of data of 143 Finnish and Russian AIP patients, the proportion of 
symptomatic patients decreased dramatically from 49% to 17% among patients diagnosed 
before and after 1980. The decrease in acute symptoms was even more prominent in male 
patients, since only two out of 21 patients (10%) diagnosed after 1980 had experienced acute 
attacks requiring hospitalisation. 
  Thirty-seven patients deceased during the follow-up (1966-2002) (Kauppinen and 
Mustajoki 1992). Of the seven patients who died during an acute attack (before 1980), three 
had died during a subsequent attack following diagnosis of AIP but had not received proper 
counseling, three other patients had died during their first severe attack at which they were at 
first misdiagnosed, and one patient had experienced recurrent attacks with no diagnosis and 
AIP was confirmed retrospectively by pedigree analysis and typical clinical symptoms. Of 
note, seven additional patients died due to hepatoma.  
Of the 46 patients who were symptomatic at the time of diagnosis 18 (39%) subjects 
experienced recurrent attacks during the follow-up. In contrast, of the 93 patients who were 
symptom-free at the time of diagnosis only five (5%) subjects experienced one or more 
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attacks during the follow-up (p<0.0001), indicating the role of an early diagnosis and a 
proper counseling in AIP.  
Neurological deficits accompanied acute attacks in 13 cases (28 %) before AIP was 
diagnosed and eight of these patients (61%) experienced subsequent acute attacks after  
diagnosis, resulting in paresis in three cases (38%). Three additional patients experienced 
paresis after diagnosis was confirmed, one of whom was symptom-free at the time of the 
diagnosis and two patients who had previously experienced acute attacks without paresis 
(Article IV, Figure II). The high number of patients with previous and subsequent paresis 
suggests a higher risk, although not significant, of neurological manifestations in those 
patients. All recurrent attacks complicated by paresis except one occurred before 1980 and 
none of them was treated with haem arginate.  
In all AIP patients normal PBG excretion predicted freedom from acute attacks. The 
risk of symptoms was highest for female patients with markedly increased PBG excretion 
(>100 μmol/l, Article IV, Table 5).  
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6. DISCUSSION 
 
6.1. SCREENING OF PATIENTS WITH ACUTE POLYNEUROPATHY OR 
ENCEPHALOPATHY 
 
Since acute porphyria is a great imitator (Waldenström 1939; Crimlisk 1997) the 
majority of patients with clinical signs and symptoms suggestive of acute porphyria have no 
inherited porphyria. These patients may have transient abnormalities in haem metabolism 
which usually manifests as mild coproporphyrinuria (Daniell et al. 1997; Bonkovsky, 
Barnard 1998). Unfortunately, misinterpretation of  such findings leads commonly to 
overestimation of inherited porphyrias.  In our series more than 100 patients with symptoms 
suggestive of acute porphyria were screened for urinary coproporphyrin and porphyrin 
precursors. Of those, 21%  of patients had elevated levels in urinalysis and 12 patients (11%) 
were diagnosed to have acute porphyria and the rest of them had mainly hepatopathy of 
various origins. Our results suggest that screening for acute porphyria using urinary PBG is 
useful in a selected neurological group including patients with acute PNP or encephalopathy, 
seizures associated with pain and dysautonomia. 
Our study represents the first prospective study of the patients with various neurological 
manifestations and screening for acute porphyria. According to the design of the study, only 
patients with neurological manifestations were screened, and thus, patients with mild attacks 
were excluded from this study group. Moreover, our Russian patient material represents a 
currently rare severe form of acute attacks in comparison with other attacks of porphyria 
(Mustajoki, Nordmann 1993; Hift, Meissner 2005), which is could be probably explained by 
design of the study and commonly delayed diagnosis of porphyria.   
Since the neurological manifestations of porphyria are polymorphic and most of the 
patients have not been examined by a neurologist, the estimate that only 5-17% of 
symptomatic patients have neurological impairment (Mustajoki, Nordmann 1993; Albers et 
al. 1978) may be too low. In South African series 57% of AIP patients experienced paresis, 
usually before admission to the hospital (Hift and Meissner 2005). In our study, of 143 
patients, 27% of symptomatic patients have experienced paresis during an acute attack, but 
more mild neurological symptoms may have been overlooked. 
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6.2. NEUROLOGICAL  MANIFESTATIONS IN AIP 
 
6.2.1. Acute peripheral neuropathy 
 
Acute PNP was the most common neurological sign during an acute attack in our series as 
well as in the other ones reported earlier (Goldberg 1959; Ridley 1969; Stein, Tschudy 1970; 
Mustajoki, Koskelo 1976; Suarez et al. 1997). In our series of 12 patients, the association of 
abdominal pain, dysautonomia, common preservation of ankle jerks and a more pronounced 
weakness in the proximal leg muscles and mild hepatopathy were the hallmarks of acute 
PNP. Similar findings were described in the series of 25 patients from the United Kingdom, 
which is the only series including patients with acute porphyria and polyneuropathy solely 
(Ridley 1969). PNP in acute porphyria has been considered pure motor (Albers, Fink 2004; 
Kasper et al. 2005), but in our patients sensory symptoms were also frequent in addition to 
muscle weakness.  In contrast to the previous series (Ridley 1969), a combination of PNS 
and CNS involvement was present in the majority of our cases indicating that neurological 
manifestations may vary individually and mild changes especially mental symptoms may be 
missed in the clinical examination.  
Based on our findings of elevated serum creatinine kinase values rhabdomyolysis is 
probably a more common aetiological factor of muscle weakness during an acute attack than 
previously reported (Marsden, Peters 2004) and it could probably attribute to the proximal 
predilection of muscle weakness in some of the cases. It is also important for physicians to 
notice, that if muscle weakness appear during an acute attack or proceed after a period of 
stabilisation of a patient’s neurological condition, the use of drugs or inadequate nutrition 
can be a cause for a patient’s deterioration.  This could be demonstrated in our patients who 
were commonly affected by both drugs and fasting resulting in progression of muscle 
weakness or seizures. Unfortunately, neurological manifestations of acute porphyria are still 
mainly iatrogenic in origin (Waldenström 1939; Mustajoki, Koskelo 1976).  
 Currently, there is no good explanation for the neurological manifestations at the 
molecular level in AIP (Meyer et al. 1998). The reversible nature of the symptoms during an 
acute attacks favours neurotoxicity of porphyrin precursors to haem deficiency (Kauppinen 
2005). A full clinical remission in a severely affected patient after liver transplantation 
(Soonawalla et al. 2004) supports the role of  porphyrin metabolites in the pathogenesis of 
neurological symptoms. Vulnerability of neuronal and vascular structures to  toxic effects of 
porphyrins and their precursors vary inter-individually (Article IV), and this may be affected 
by other genes related to neuronal resistance (Huang et al. 1999) or to efflux systems of 
porphyrin metabolism (von und zu Fraunberg et al. 2002).  
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6.2.2. Neurophysiological findings 
 
Despite porphyric neuropathy being considered axonal (Albers, Fink 2004), distinct 
demyelinating features were revealed in nerve conduction studies even at the onset of PNP in 
our patient. Decreased MCVs, which have often been reported also in previous series (Table 
7) (Maytham, Eales 1971; Flugel, Druschky 1977; Wochnik-Dyjas et al. 1978), have been 
considered to be secondary to the primary axonal damage, and thus, a late complication in 
AIP. Severe demyelination, which was found in our patient’s early phase of PNP, raises a 
question of a possible role of primary demyelination in some cases of acute PNP in AIP. In 
three patients of ours, demyelination associated with the clinical severity of neuropathy 
rather than with duration of it. Abnormal sensory evoked potentials which were found in our 
patients and described earlier in at least ten additional patients tested with sensory nerve 
conduction studies (Table 7) (Albers et al. 1978; Wochnik-Dyjas et al. 1978; Barohn et al. 
1994; King et al. 2002), support our clinical findings that sensorimotor PNP is common in 
AIP and should be found during the physical examination of a patient.  
The reinnervation pattern which was demonstrated early during the first 
episode of acute PNP and the mild transient conduction slowing in patients with no evident 
PNP during acute attack suggest that peripheral nerves may be affected preceding or even 
without clinical PNP in AIP. The similar reinnervation pattern found in an additional patient 
(Nagler 1971) supports this finding.  
The mechanism of primary demyelination in AIP could be related to an increased 
free radical formation because of ALA auto-oxidation (Demasi et al. 1996; Smith et al. 
1999), occurring, however, only at the high concentrations (Demasi et al. 1996). This could 
explain our finding that demyelination was present mainly  in severe cases of acute PNP, 
who had at least 3-fold excretion of ALA even in remission. Inhibition of Na+/K+ ATPase 
and a high affinity to glutamate receptors by ALA  has been demonstrated in CNS (Brennan, 
Cantrill 1981; Russel et al. 1983), which could be attributed to the peripheral nerves causing 
slowing of conduction (Cleland 1996; Djemli-Shipkolye et al. 2001) (Article II, Figure 3).  
Previous findings of autopsies (Denny-Brown, Sciarra 1945; Drury 1956; 
Gibson, Goldberg 1956; Cavanagh, Mellick 1965) are in agreement with our 
electrophysiological data suggesting that demyelination of peripheral nerves may appear 
primarily in combination with primary axonopathy.   
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6.2.3. Neuroimaging 
 
Posterior reversible encephalopathy syndrome (PRES) is the main finding in the brain MRI 
during an acute attack (King, Bragdon 1991; Aggarwal et al. 1994; Black et al. 1995; 
Kupferschmidt et al. 1995; Garg et al. 1999; Susa et al. 1999; Utz et al. 2001; Celik et al. 
2002; Yen et al. 2002; Engelhardt et al. 2004; Maramattom et al. 2005; Wessels et al. 2005). 
This was clearly demonstrated also in our two patients with encephalopathy. PRES suggests 
breakage of blood-brain barrier (Lamy et al. 2004) in AIP patients, which permits access of 
neurotoxins such as ALA to neurons. The exact mechanism of permeability impairment has 
not been studied in AIP.  
The pattern of encephalopathy in AIP is usually related to localisation of oedema. For 
example blurred vision has been reported in the cases with occipital oedema (Kupferschmidt 
et al. 1995; Yen et al. 2002; Wessels et al. 2005). Of the seven patients who had signs of 
CNS involvement such as seizures and confusion during an acute attack and were studied by 
neuroimaging in our series, no lesions could be demonstrated in five cases. The possible 
explanations include delayed neuroimaging and short-lasting oedema in those patients, as 
well as not sufficient resolution to detect small oedema without special techniques such as 
FLAIR, DW and contrast enhancement. However, the possibility that not all the patients with 
acute encephalopathy during an acute attack have vasogenic oedema could not be ruled out. 
PRES could explain seizures in AIP. The previous hypothesis of hyponatraemia as the main 
cause of seizures in AIP (Solinas, Vajda 2004) is unlikely, since severe hyponatraemia of 
less than 125 mmol/L (Wijdicks, Sharbrough 1993) occurs less frequently than seizures 
(Bylesjo et al. 1996). 
 
6.2.4. Pain during an acute attack  
 
The intensity of pain by VAS was scored in our patients with AIP during an acute attack. 
The adequate evaluative and discriminative properties of scaling have been demonstrated in 
other diseases (Villanueva et al. 2004). According to our results, patients with AIP and acute 
PNP had severe abdominal pain scored as 7-10 accompanied by muscle weakness or 
preceding it.  
Acute PNP without abdominal pain is a rare phenomenon (Goren, Chen 1991; 
Niznikievicz, Jablonska-Kaszewska 1996; Cohen et al. 1997; Andersson et al. 2002) and 
none of our patients experienced it. In two cases of acute porphyric encephalopathy without 
PNP abdominal pain was absent or very mild. Few such cases have been reported previously 
(Kupferschmidt et al. 1995; Engelhardt et al. 2004) suggesting that acute encephalopathy and 
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polyneuropathy may have different mechanisms in AIP.   
Myalgic or dysesthetic pain in the extremities were common and lasted usually for 1-
2 weeks following muscle weakness. This temporal association has not been described 
previously and could suggest that this type of pain is related to muscle weakness similar  to 
myalgias described in Guillain-Barré syndrome (Moulin et al. 1997). 
 
6.2.5. Scaling of an acute attack 
 
Based on our patient data we have developed a scale in order to evaluate the severity and the 
prognosis of an acute porphyric attack. Scoring can easily be applied to the bed-side follow-
up of a patient, and certain symptoms such as severe muscle weakness, bulbar palsy, 
impairment of consciousness and severe hyponatraemia should alert a medical personnel to 
transfer a patient into an intensive care unit. Although arrhythmia was the cause of death in 
one of our patients, the number of the patients was too small to draw final conclusions of the 
severity of arrhythmias for the prognosis. Thus, arrhythmia could not be in the list of alerting 
signs of an acute attack, but is most likely a sign of more severe dysautonomia as reported in 
Guillain-Barré syndrome (Flachenecker et al. 2001).  Many other dramatic symptoms such as 
pain, vomiting, constipation and mental symptoms had no effect on the prognosis. During an 
acute attack the follow-up of pulse (Ridley et al. 1968) and scaling of pain using VAS are the 
useful bed-side tools to evaluate the activity and recovery from an acute attack.   
 
6.3. THE DIAGNOSTICS OF AIP  
 
The combination of clinical symptoms and biochemical findings is mandatory in order to 
diagnose acute attack of AIP (Kauppinen 2005). Misdiagnosis is possible if the analysis is 
based only on qualitative methods of PBG detection. False positive results are common 
(33%) (Thunell et al. 2000) because of increased urobilinogen, presence of pH indicators, 
such as phenazopyridinium chloride, methyl red or urosein, in the urine, or medications 
which  produce red colour of urine in the presence of Ehrlich’s reagent (Bonkovsky, Barnard 
1998). False negative results may appear especially if samples are not shielded from the light 
properly or analysis is delayed.  
The algorithm of diagnostics of AIP is presented in Table 27. 
In the earlier series of patients with AIP and neurological manifestations, the 
diagnosis of AIP was based on reliable quantitative urinalyses of porphyrin precursors in the 
several series (Stein, Tschudy 1970; Mustajoki, Koskelo 1976; Flugel, Druschky 1977; 
Albers et al. 1978; Wochnik-Dyjas et al. 1978). Thus, the diagnosis of neurological 
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manifestations resulted from an acute attack was correct. In the other studies, only qualitative 
screening test was used to screen urinary PBG (Goldberg 1959; Ridley 1969) or excretions 
were normal (Tan et al. 1990; Goren, Chen 1991; Crimlisk 1997; Engelhardt et al. 2004) or 
not measured (Cohen et al. 1997; Utz et al. 2001; Yen et al. 2002). Thus, the diagnosis of 
acute porphyria was not always confirmed according to the current criteria (Kauppinen 
2005). In our series the diagnosis of AIP was established by modern biochemical and 
genetical testing in remission and increased urinary PBG excretion and typical clinical 
manifestations could be demonstrated during an acute attack. All of them are mandatory 
before the final diagnosis of  acute porphyria as a cause of  polyneuropathy or 
encephalopathy can be made. If more strict inclusion criteria for biochemical abnormalities 
are required (Thunell et al. 2000; Kauppinen 2005), neurological manifestations of acute 
porphyria are probably more homogeneous than described previously.  
 
Table  27. The algorithm of diagnostics of AIP 
 
I. When to screen for 
acute porphyria 
Symptoms or signs 
 Acute abdominal or back pain and   
PNP or encephalopathy or dysautonomia or seizures or SIADH.  
Usually more than one symptom 
II. What to screen  
U-PBG: if >5-fold, the diagnosis of acute porphyria is likely A. During an acute attack 
U-PBG is normal but U-ALA is increased, look for lead intoxication 
             P-porphyrin spectrum: positive 
(AIP, HCP and porphyria cutanea tarda: 615-620 nm; VP: 624-627 nm) 
 
   Additional tests 
  if precursors are positive 
F-coproporphyrin (AIP normal*, HCP↑↑↑ I << III †, VP ↑↑† ‡)  
F-protoporphyrin (AIP normal or < 2-fold*, VP ↑↑↑, HCP < 2-fold‡) 
 U-uroporphyrin ↑↑↑  >> U-coproporphyrin ↑ in AIP* 
 if increased but U-ALA or U-PBG are normal, exclude secondary 
porphyrinuria 
 
 B. During remission Repeat biochemical tests (abnormal in 88% of patients in remission*) 
 Erc-HMBS activity low, but in the variant form (5-16%) is normal*§ 
 DNA analysis and family screening if a specific mutation is found 
 
*(Kauppinen, von und zu Fraunberg 2002), †(Kuhnel et al. 2000), ‡ (Mustajoki 1980; von und zu 
Fraunberg et al. 2002), § (Whatley et al. 2000). 
 
Mutation analysis is currently used in routine analysis of AIP in remission and in the 
family studies (Kauppinen, von und zu Fraunberg 2002) despite high allelic heterogeneity of 
the mutations in the HMBS gene.  In our patients series nine different mutations including 
five amino acid substitutions, nonsense mutation and three novel splicing defects 
(c.825+5G>C, c.825+3_6del, c.770T>C) were identified in 11 Russian AIP patients. 
Screening of them can be used in the genetic counseling of these families in order to find the 
individuals at risk. Most of the mutations were family-specific,  although  the majority of 
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them has been found also in the Western and other Eastern European populations (Lee, 
Anvert 1991; Llewellyn et al. 1993; Mgone et al. 1993; Kauppinen et al. 1995; Lundin et al. 
1995; Rosipal et al. 1997; Gregor et al. 2002). This suggests that mutations may have 
originated from other parts of Europe or they may have appeared de novo. The diversity of 
the mutations may reflect an old international history of St Petersburg where immigration of 
various professionals was common in the 18 and 19th centuries (Chesnokova 2003) 
The causality of the novel mutations should always be proven in expression studies 
(Mustajoki et al. 2000). In our study enzyme activities of the mutants have been decreased to 
0.1-1.3% of the wild type activity which confirms the causality of the mutations in these 
families. 
 
6.4.DIFFERENTIAL DIAGNOSIS OF ACUTE POLYNEUROPATHY AND 
ENCEPHALOPATHY 
 
The combination of typical signs and symptoms (Ridley 1969) is pathognomonic for AIP, 
but pain, dysautonomia, hyponatraemia and even mental symptoms may also be present in 
other polyneuropathies (Ferraro-Herrera et al. 1997; Moulin et al. 1997; Colls 2003; Cochen 
et al. 2005, http://www.neuro.wustl.edu/neuromuscular/). Thus, no clinical features can 
ultimately exclude AIP in a patient with acute PNP. Thus, screening of urinary PBG should 
be performed in any patient with acute PNP. In addition, patients with  a combination of 
acute encephalopathy, dysautonomia or pain should be screened for urinary PBG during a 
symptomatic phase (Table 27). 
Abnormal metabolism of porphyrin and their precursors may be also detected in 
patients with  non-inherited conditions, so-called secondary porphyrinuria (Daniell et al. 
1997; Bonkovsky, Barnard 1998) (Table 28). They usually manifest as mild to moderate 
transient coproporphyrinuria, but porphyrin precursors are not markedly elevated (Daniell et 
al. 1997). Lead intoxication is an exception, because urinary ALA is usually significantly 
elevated (Godwin 2001).  
Secondary porphyrinuria has been suggested to cause neurological manifestations 
(Oberndorfer et al. 2002; Ahle et al. 2005), but this is very unlikely, since porphyrins per se 
do not cause neurological manifestations in patients with cutaneous symptoms of porphyria 
and high amounts of porphyrins in the circulation (Schmidt et al. 1974; Anderson et al. 
2001). In the majority of the cases of secondary porphyrinuria,  neurological manifestations 
could be explained by other reasons (Table 28) (Khella, Souayah 2002; Kucera et al. 2002). 
 
 
 86
Table 28. Secondary porphyrinuria and their neurological manifestations*  
 
Diagnosis Common features with 
porphyria 
Specific features Pathogenesis 
Lead 
intoxication 
Acute PNP + 
autonomic features ± 
pain ± brain oedema  
U-ALA ↑↑↑ + 
U-coproporphyrin ↑↑  
B-Pb ↑↑ 
Zinc protoporphyrin ↑↑ 
Erc-ALAD activity ↓↓↓ 
Erythrocyte punctation 
Haemoglobin ↓ 
1) ALAD activity ↓↓↓ causing 
accumulation of ALA 
2) Neurological manifestations 
are mainly due to ALA ↑↑↑, but 
inhibition of several Ca-binding 
proteins is also important 
 
Thallium. 
arsenic 
intoxication 
Acute PNP + 
autonomic features ± 
pain ± brain oedema  
U-coproporphyrin ↑↑  ±  
U-uroporphyrin ↑↑ 
Urinary metals ↑↑. 
Alopecia in chronic 
thallium intoxication 
(absent in acute 
intoxication) 
1) Coproporphyrinogen oxidase 
or/and uroporphyrinogen 
deaminase activities ↓↓↓.  
2) Neurological impairment 
independent of porphyrins  
 
Alcohol 
intoxication  
Autonomic features ± 
acute PNP ± pain ± 
brain oedema  
U-coproporphyrin ↑↑ 
Elevated levels of 
alcohol in plasma 
1) Coproporphyrinogen oxidase 
or/and uroporphyrinogen 
decarboxylase activities ↓↓↓.  
2) Direct neurotoxicity 
 
Liver 
diseases 
(cirrhosis. 
hepatitis etc) 
Autonomic features  ± 
acute PNP ± pain ± 
brain oedema  
U-coproporphyrin ↑↑ 
Specific signs of the 
liver disease 
1) Defect of elimination of 
porphyrins from the liver  
2) Neurological impairment 
independent of porphyrins 
 
Anaemias 
(hemolytic, 
aplastic, 
pernicious), 
Leukemias/ 
lymphomas 
Autonomic features  ± 
acute PNP ± pain ± 
brain oedema +  
P-protoporphyrin ↑↑ ±  
↑ U-PBG/ALA 
Specific signs of 
anaemia 
1) Defect in terminal stage of 
haem synthesis in the bone 
marrow  
2) Neurological impairment 
independent of porphyrins 
 
*(Prato et al. 1968; Campbell et al. 1978; Daniell et al. 1997; Bonkovsky, Barnard 1998; Godwin 
2001; Khella, Souayah 2002; Kucera et al. 2002). 
 
6.5. PROGNOSIS OF AIP 
 
Our patients represent severe cases of AIP who were undiagnosed at the onset of the disease. 
The duration of diagnostic delay of an acute attack correlated with a fatal outcome in two 
cases mainly due to the administration of drugs known to precipitate AIP for misdiagnosed 
attack. The causes of death were related to complications of prolonged ventilation and 
cardiac dysautonomia similarly to the previous series (Goldberg 1959; Ridley 1969; 
Mustajoki, Koskelo 1976). The majority of our patients (83%) had full functional recovery 
even after a severe attack  Both mortality and neurological sequels have been lower in our 
series (14% and 17%, respectively), than in previous series (35-48% and 24-50%, 
respectively) when patients with neurological manifestations solely have been included 
(Goldberg 1959; Ridley 1969; Sorensen, With 1971; Mustajoki, Koskelo 1976).  
Currently, the overall prognosis of AIP is good. The mortality during an acute attack 
has decreased dramatically during the last decades among diagnosed AIP patients 
(Kauppinen, Mustajoki 1992) (Article IV) and thus, DNA diagnostics among family 
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members is recommended before the adulthood since it decreases the likelihood of a 
manifest disease to 5% in patients diagnosed at the presymptomatic phase. However, the 
mortality of AIP patients is around 5-20% during an acute attack (Kauppinen, Mustajoki 
1992; Jeans et al. 1996; Hift and Meissner 2005) and physicians should be aware of a 
potentially fatal outcome of a patient.   
 
6.6. THE GENOTYPE-PHENOTYPE CORRELATION 
 
The recent characterization of  genotypes in the families with AIP has raised a question 
whether the genotype affects the phenotype in these individuals. We have demonstrated, that 
two mutations p.R167W and p.R225G resulted in a milder phenotype in terms of both 
clinical manifestations and biochemical abnormalities when compared with other eight 
mutations studied (c.33G>T, c.97delA, InsAlu333, p.R149X, p.R173W, p.R173Q, p.R225X 
and c.1073delA). Our results support the previous conclusion that patients with the mutation 
p.R167W have milder clinical manifestations than those with the p.R173W and p.W198X 
mutations (Andersson et al. 2000).  
Some parameters such as low urinary excretion of porphyrin precursors (PBG<100 
µmol/L) and milder mutations, have predictive values and can be applied directly for clinical 
use. Normal urinary PBG excretion predicted freedom from acute attacks (Kauppinen, 
Mustajoki 1992), in a current series also supporting the theory that porphyrin precursors are 
crucial in the pathogenesis of clinical manifestations (Meyer et al. 1998).  
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7. CONCLUSIONS 
 
The study describes neurological manifestations and molecular genetics of AIP in North 
Western Russia. The main results are summarised as follows: 
 
7.1. Clinical manifestations of an acute attack 
• Screening for acute porphyria using urinary PBG is useful in a selected neurological 
group including patients with acute peripheral neuropathy (PNP) or encephalopathy 
and seizures associated with pain and dysautonomia. 
• The most common neurological symptom of an acute attack is PNP. Despite 
heterogeneity of the manifestations of PNP in acute porphyria, the major pattern of 
PNP associated with abdominal pain, dysautonomia, CNS involvement and mild 
hepatopathy could be demonstrated. If more strict inclusion criteria for biochemical 
abnormalities are applied (>10-fold increase in excretion of urinary PBG) are applied, 
neurological manifestations in an acute attack are probably more homogeneous than 
described previously, which suggests that some of the neurological patients described 
previously may not have acute porphyria but rather secondary porphyrinuria.  
 
7.2. Scaling and prognosis of an acute attack 
• A 30-score scale was proposed for the severity of an acute attack. This scale can 
easily be used in clinical practice and can be used internationally in order to 
standardise the outcome of an attack.  
• Degree of muscle weakness, prolonged mechanical ventilation, bulbar paralysis, 
impairment of consciousness and hyponatraemia were important signs of a poor 
prognosis. Arrhythmia was less important and autonomic dysfunction and mental 
symptoms did not affect the outcome.  
• The delay in the diagnosis and repeated administrations of precipitating factors were 
the main cause of proceeding of an acute attack into pareses and severe CNS 
involvement.   
 
7.3. Neurophysiological studies and neuroimaging  
• Features suggestive of demyelination could be demonstrated in addition to 
axonopathy in patients with severe PNP during an acute attack. PNP with a moderate 
muscle weakness was mainly pure axonal. Sensory involvement was common in 
acute PNP and could be subclinical. Decreased conduction velocities with normal 
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amplitudes of evoked potentials during acute attacks with no clinically evident PNP 
indicate subclinical polyneuropathy. 
• Reversible symmetrical lesions comparable with posterior reversible encephalopathy 
syndrome (PRES) were revealed in two patients’ brain CT or MRI during an acute 
attack. In other five patients brain MRI during or soon after the symptoms was 
normal. The frequency of reversible brain oedema in AIP is probably under-estimated 
since it may be short-lasting and often indistinguishable on CT or MRI.    
 
7.4. Mutation spectrum of AIP patients in North Western Russia 
• Nine different mutations, including five amino acid substitutions, nonsense mutation 
and three novel splicing defects (c.825+5G>C, c.825+3_6del and c.770T>C) were 
identified among Russian AIP patients. In two of three novel mutations [c.885+5G>C 
and c.770T>C] abnormal cDNA sequences could be identified.  
• The normal and nine mutant polypeptides were expressed in COS-1 cells. Enzyme 
activities of all mutated alleles were decreased to 0.1-1.3% of the wild type activity, 
confirming the causality of the mutations. 
 
7.5. The genotype-phenotype correlation of mutation type and biochemical and clinical 
findings 
• Two mutations, p.R167W and p.R225G, resulted in a milder phenotype in terms of 
both clinical manifestations and biochemical abnormalities in comparison with the 
eight mutations studied (c.33G>T. C.97delA. InsAlu333. p.R149X. p.R173W. 
p.R173Q. p.R225X. c.1073delA).  
• Erythrocyte HMBS activity did not correlate with the porphobilinogen excretion in 
remission or with clinical severity of the disease. 
• Urinary PBG excretion together with gender, age at the time of diagnosis and 
mutation type may predict the likelihood of acute attacks in AIP patients.  
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